{"transactions":[{"id":693147,"issuer":{"id":3756,"kind":"organization","name":"Bausch & Lomb Corp"},"owners":[{"id":11572,"kind":"person","name":"SAUNDERS BRENT L","position":1,"cik":"0001268854","reported_name":"SAUNDERS BRENT L","relationship":{"director":true,"officer":true,"officer_title":"Chairman of the Board and CEO"}}],"security":"Common Shares, No Par Value","published_at":"2026-08-07T20:30:19.000Z","date":"2026-08-05","kind":"grant","planned":false,"acquired":true,"shares":281879,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents common shares, no par value, of Bausch + Lomb Corporation underlying an award of performance stock units (\"PSUs\") originally granted to the reporting person on February 28, 2024 under the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan, as amended and restated, that satisfied the applicable performance conditions at the target performance level (100%) as of August 5, 2026. The earned PSUs will vest on February 28, 2027, subject generally to the reporting person's continued employment through such date."}],"balance_after":1256037,"source":{"system":"sec-edgar","filing":"0001860742-26-000089","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1860742/000186074226000089/form4.xml","form_type":"4"}},{"id":693146,"issuer":{"id":3756,"kind":"organization","name":"Bausch & Lomb Corp"},"owners":[{"id":11572,"kind":"person","name":"SAUNDERS BRENT L","position":1,"cik":"0001268854","reported_name":"SAUNDERS BRENT L","relationship":{"director":true,"officer":true,"officer_title":"Chairman of the Board and CEO"}}],"security":"Common Shares, No Par Value","published_at":"2026-08-07T20:30:19.000Z","date":"2026-08-05","kind":"tax_withholding","planned":false,"acquired":false,"shares":4231,"price":16.76,"value":70911.56,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This number represents common shares withheld to satisfy the tax withholding obligations due upon vesting of restricted share units."}],"balance_after":974158,"source":{"system":"sec-edgar","filing":"0001860742-26-000089","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1860742/000186074226000089/form4.xml","form_type":"4"}},{"id":725472,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":11572,"kind":"person","name":"SAUNDERS BRENT L","position":1,"cik":"0001268854","reported_name":"SAUNDERS BRENT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-26T20:15:11.000Z","date":"2026-06-24","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest in full on the earlier of June 24, 2027 or the date of the Issuer's 2027 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors."}],"balance_after":30000,"derivative":{"exercise_price":10.54,"expiration_date":"2036-06-23","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001268854-26-000002","document":"form4-06262026_040607.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000126885426000002/form4-06262026_040607.xml","form_type":"4"}},{"id":763970,"issuer":{"id":3756,"kind":"organization","name":"Bausch & Lomb Corp"},"owners":[{"id":11572,"kind":"person","name":"SAUNDERS BRENT L","position":1,"cik":"0001268854","reported_name":"SAUNDERS BRENT L","relationship":{"director":true,"officer":true,"officer_title":"Chairman of the Board and CEO"}}],"security":"Common Shares, No Par Value","published_at":"2026-05-26T20:56:11.000Z","date":"2026-05-22","kind":"tax_withholding","planned":false,"acquired":false,"shares":2886,"price":15.92,"value":45945.12,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This number represents common shares withheld to satisfy the tax withholding obligations due upon vesting of restricted share units."}],"balance_after":978389,"source":{"system":"sec-edgar","filing":"0001860742-26-000071","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1860742/000186074226000071/form4.xml","form_type":"4"}},{"id":851183,"issuer":{"id":3756,"kind":"organization","name":"Bausch & Lomb Corp"},"owners":[{"id":11572,"kind":"person","name":"SAUNDERS BRENT L","position":1,"cik":"0001268854","reported_name":"SAUNDERS BRENT L","relationship":{"director":true,"officer":true,"officer_title":"CEO and Chairman of the Board"}}],"security":"Common Shares, No Par Value","published_at":"2026-03-10T20:32:06.000Z","date":"2026-03-06","kind":"grant","planned":false,"acquired":true,"shares":14700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents matching restricted share units (\"MRSUs\") granted to the reporting person in connection with the open market purchase of common shares reported on Table I above, pursuant to the issuer's matching share program. One-third of the MRSUs will vest on each of the first, second, and third anniversaries following the date of grant, subject to the reporting person's continued service (except in limited circumstances)."}],"balance_after":981275,"source":{"system":"sec-edgar","filing":"0001860742-26-000054","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1860742/000186074226000054/form4.xml","form_type":"4"}},{"id":851182,"issuer":{"id":3756,"kind":"organization","name":"Bausch & Lomb Corp"},"owners":[{"id":11572,"kind":"person","name":"SAUNDERS BRENT L","position":1,"cik":"0001268854","reported_name":"SAUNDERS BRENT L","relationship":{"director":true,"officer":true,"officer_title":"CEO and Chairman of the Board"}}],"security":"Common Shares, No Par Value","published_at":"2026-03-10T20:32:06.000Z","date":"2026-03-06","kind":"purchase","planned":false,"acquired":true,"shares":14700,"price":17.14,"value":251958.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects a weighted average price. These shares were purchased in multiple transactions at prices ranging from $17.09 to $17.19 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above."}],"balance_after":966575,"source":{"system":"sec-edgar","filing":"0001860742-26-000054","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1860742/000186074226000054/form4.xml","form_type":"4"}},{"id":874458,"issuer":{"id":3756,"kind":"organization","name":"Bausch & Lomb Corp"},"owners":[{"id":11572,"kind":"person","name":"SAUNDERS BRENT L","position":1,"cik":"0001268854","reported_name":"SAUNDERS BRENT L","relationship":{"director":true,"officer":true,"officer_title":"CEO and Chairman of the Board"}}],"security":"Common Shares, No Par Value","published_at":"2026-03-02T22:44:02.000Z","date":"2026-02-27","kind":"tax_withholding","planned":false,"acquired":false,"shares":24649,"price":18.3,"value":451076.7,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This number represents common shares withheld to satisfy the tax withholding obligations due upon vesting of restricted share units."}],"balance_after":951875,"source":{"system":"sec-edgar","filing":"0001860742-26-000041","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1860742/000186074226000041/form4.xml","form_type":"4"}},{"id":874457,"issuer":{"id":3756,"kind":"organization","name":"Bausch & Lomb Corp"},"owners":[{"id":11572,"kind":"person","name":"SAUNDERS BRENT L","position":1,"cik":"0001268854","reported_name":"SAUNDERS BRENT L","relationship":{"director":true,"officer":true,"officer_title":"CEO and Chairman of the Board"}}],"security":"Common Shares, No Par Value","published_at":"2026-03-02T22:44:02.000Z","date":"2026-02-26","kind":"tax_withholding","planned":false,"acquired":false,"shares":22059,"price":18.49,"value":407870.91,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This number represents common shares withheld to satisfy the tax withholding obligations due upon vesting of restricted share units."}],"balance_after":976524,"source":{"system":"sec-edgar","filing":"0001860742-26-000041","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1860742/000186074226000041/form4.xml","form_type":"4"}},{"id":877460,"issuer":{"id":3756,"kind":"organization","name":"Bausch & Lomb Corp"},"owners":[{"id":11572,"kind":"person","name":"SAUNDERS BRENT L","position":1,"cik":"0001268854","reported_name":"SAUNDERS BRENT L","relationship":{"director":true,"officer":true,"officer_title":"CEO and Chairman of the Board"}}],"security":"Common Shares, No Par Value","published_at":"2026-02-27T21:03:02.000Z","date":"2026-02-25","kind":"grant","planned":false,"acquired":true,"shares":327102,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects the grant of restricted share units (\"RSUs\") under the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan (as amended and restated, the \"Plan\") which are scheduled to vest one-third on each of the first three anniversaries of the date of grant, subject generally to the reporting person's continued service and the terms of the Plan and the applicable award agreement thereunder. Vested RSUs are settled in common shares, no par value, of Bausch + Lomb Corporation."}],"balance_after":998583,"source":{"system":"sec-edgar","filing":"0001860742-26-000028","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1860742/000186074226000028/form4.xml","form_type":"4"}},{"id":882157,"issuer":{"id":3756,"kind":"organization","name":"Bausch & Lomb Corp"},"owners":[{"id":11572,"kind":"person","name":"SAUNDERS BRENT L","position":1,"cik":"0001268854","reported_name":"SAUNDERS BRENT L","relationship":{"director":true,"officer":true,"officer_title":"CEO and Chairman of the Board"}}],"security":"Common Shares, No Par Value","published_at":"2026-02-25T21:58:50.000Z","date":"2026-02-23","kind":"tax_withholding","planned":false,"acquired":false,"shares":65444,"price":17.99,"value":1177337.56,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This number represents common shares withheld to satisfy the tax withholding obligations due upon vesting of restricted share units."}],"balance_after":671481,"source":{"system":"sec-edgar","filing":"0001860742-26-000027","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1860742/000186074226000027/form4.xml","form_type":"4"}},{"id":1072366,"issuer":{"id":3756,"kind":"organization","name":"Bausch & Lomb Corp"},"owners":[{"id":11572,"kind":"person","name":"SAUNDERS BRENT L","position":1,"cik":"0001268854","reported_name":"SAUNDERS BRENT L","relationship":{"director":true,"officer":true,"officer_title":"CEO and Chairman of the Board"}}],"security":"Common Shares, No Par Value","published_at":"2025-08-07T20:23:09.000Z","date":"2025-08-05","kind":"tax_withholding","planned":false,"acquired":false,"shares":4231,"price":14.44,"value":61095.64,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This number represents common shares withheld to satisfy the tax withholding obligations due upon vesting of restricted share units."}],"balance_after":736925,"source":{"system":"sec-edgar","filing":"0001127602-25-020237","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1860742/000112760225020237/form4.xml","form_type":"4"}},{"id":1082850,"issuer":{"id":3756,"kind":"organization","name":"Bausch & Lomb Corp"},"owners":[{"id":11572,"kind":"person","name":"SAUNDERS BRENT L","position":1,"cik":"0001268854","reported_name":"SAUNDERS BRENT L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and Chairman of the Board"}}],"security":"Performance Stock Units","published_at":"2025-07-23T21:35:29.000Z","date":"2025-07-21","kind":"grant","planned":false,"acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Reflects an amendment on July 21, 2025 (the \"Amendment\") to an award of performance stock units (\"PSUs\") originally granted to the reporting person under the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan (as amended and restated, the \"Plan\") on February 23, 2023 (the \"New Hire PSUs\").  Each PSU reflects the right to receive one common share, no par value, of the Issuer, subject to the terms of the Plan."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Pursuant to the Amendment, the New Hire PSUs may be earned and vest between 120% and 330% of the target award on February 23, 2029 (the \"Measurement End Date\") based on the level of achievement of (i) specified share-price hurdle goals and (ii) a cumulative Adjusted EBITDA performance modifier goal, subject generally to the reporting person's continued employment through the Measurement End Date."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The reporting person previously reported beneficial ownership of the target number of common shares underlying the New Hire PSUs (750,000 common shares) in the reporting person's Form 3 filed on March 6, 2023. As a result of the Amendment, the reporting person is now reporting the acquisition of beneficial ownership of an additional 150,000 PSUs pursuant to the New Hire PSU, which collectively reflects beneficial ownership of the minimum number of shares that are eligible to vest on the Measurement End Date (900,000 common shares) as a result of the Amendment."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Reflects an amendment on July 21, 2025 (the \"Amendment\") to an award of performance stock units (\"PSUs\") originally granted to the reporting person under the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan (as amended and restated, the \"Plan\") on February 23, 2023 (the \"New Hire PSUs\").  Each PSU reflects the right to receive one common share, no par value, of the Issuer, subject to the terms of the Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Amendment, the New Hire PSUs may be earned and vest between 120% and 330% of the target award on February 23, 2029 (the \"Measurement End Date\") based on the level of achievement of (i) specified share-price hurdle goals and (ii) a cumulative Adjusted EBITDA performance modifier goal, subject generally to the reporting person's continued employment through the Measurement End Date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The reporting person previously reported beneficial ownership of the target number of common shares underlying the New Hire PSUs (750,000 common shares) in the reporting person's Form 3 filed on March 6, 2023. As a result of the Amendment, the reporting person is now reporting the acquisition of beneficial ownership of an additional 150,000 PSUs pursuant to the New Hire PSU, which collectively reflects beneficial ownership of the minimum number of shares that are eligible to vest on the Measurement End Date (900,000 common shares) as a result of the Amendment."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Reflects an amendment on July 21, 2025 (the \"Amendment\") to an award of performance stock units (\"PSUs\") originally granted to the reporting person under the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan (as amended and restated, the \"Plan\") on February 23, 2023 (the \"New Hire PSUs\").  Each PSU reflects the right to receive one common share, no par value, of the Issuer, subject to the terms of the Plan."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the Amendment, the New Hire PSUs may be earned and vest between 120% and 330% of the target award on February 23, 2029 (the \"Measurement End Date\") based on the level of achievement of (i) specified share-price hurdle goals and (ii) a cumulative Adjusted EBITDA performance modifier goal, subject generally to the reporting person's continued employment through the Measurement End Date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The reporting person previously reported beneficial ownership of the target number of common shares underlying the New Hire PSUs (750,000 common shares) in the reporting person's Form 3 filed on March 6, 2023. As a result of the Amendment, the reporting person is now reporting the acquisition of beneficial ownership of an additional 150,000 PSUs pursuant to the New Hire PSU, which collectively reflects beneficial ownership of the minimum number of shares that are eligible to vest on the Measurement End Date (900,000 common shares) as a result of the Amendment."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Reflects an amendment on July 21, 2025 (the \"Amendment\") to an award of performance stock units (\"PSUs\") originally granted to the reporting person under the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan (as amended and restated, the \"Plan\") on February 23, 2023 (the \"New Hire PSUs\").  Each PSU reflects the right to receive one common share, no par value, of the Issuer, subject to the terms of the Plan."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"Pursuant to the Amendment, the New Hire PSUs may be earned and vest between 120% and 330% of the target award on February 23, 2029 (the \"Measurement End Date\") based on the level of achievement of (i) specified share-price hurdle goals and (ii) a cumulative Adjusted EBITDA performance modifier goal, subject generally to the reporting person's continued employment through the Measurement End Date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"The reporting person previously reported beneficial ownership of the target number of common shares underlying the New Hire PSUs (750,000 common shares) in the reporting person's Form 3 filed on March 6, 2023. As a result of the Amendment, the reporting person is now reporting the acquisition of beneficial ownership of an additional 150,000 PSUs pursuant to the New Hire PSU, which collectively reflects beneficial ownership of the minimum number of shares that are eligible to vest on the Measurement End Date (900,000 common shares) as a result of the Amendment."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Reflects an amendment on July 21, 2025 (the \"Amendment\") to an award of performance stock units (\"PSUs\") originally granted to the reporting person under the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan (as amended and restated, the \"Plan\") on February 23, 2023 (the \"New Hire PSUs\").  Each PSU reflects the right to receive one common share, no par value, of the Issuer, subject to the terms of the Plan."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Pursuant to the Amendment, the New Hire PSUs may be earned and vest between 120% and 330% of the target award on February 23, 2029 (the \"Measurement End Date\") based on the level of achievement of (i) specified share-price hurdle goals and (ii) a cumulative Adjusted EBITDA performance modifier goal, subject generally to the reporting person's continued employment through the Measurement End Date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The reporting person previously reported beneficial ownership of the target number of common shares underlying the New Hire PSUs (750,000 common shares) in the reporting person's Form 3 filed on March 6, 2023. As a result of the Amendment, the reporting person is now reporting the acquisition of beneficial ownership of an additional 150,000 PSUs pursuant to the New Hire PSU, which collectively reflects beneficial ownership of the minimum number of shares that are eligible to vest on the Measurement End Date (900,000 common shares) as a result of the Amendment."}],"balance_after":900000,"derivative":{"underlying":"Common Shares, No Par Value","underlying_shares":900000},"source":{"system":"sec-edgar","filing":"0000950170-25-097980","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1860742/000095017025097980/ownership.xml","form_type":"4"}},{"id":1100213,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":11572,"kind":"person","name":"SAUNDERS BRENT L","position":1,"cik":"0001268854","reported_name":"SAUNDERS BRENT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-27T20:30:13.000Z","date":"2025-06-25","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest in full on the earlier of June 25, 2026 or the date of the Issuer's 2026 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors."}],"balance_after":30000,"derivative":{"exercise_price":17.26,"expiration_date":"2035-06-24","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001415889-25-018384","document":"form4-06272025_040607.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588925018384/form4-06272025_040607.xml","form_type":"4"}},{"id":1106976,"issuer":{"id":6863,"kind":"organization","name":"SkinHealth Systems Inc.","symbol":"SKIN"},"owners":[{"id":11572,"kind":"person","name":"SAUNDERS BRENT L","position":1,"cik":"0001268854","reported_name":"SAUNDERS BRENT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Chairman"}}],"security":"Class A Common Stock","published_at":"2025-06-18T20:34:00.000Z","date":"2025-06-16","kind":"grant","planned":false,"acquired":true,"shares":73051,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a grant of restricted stock units (\"RSUs\"). The RSUs vest on the earlier of the one-year anniversary of the grant and the date of the 2026 Annual Meeting of Stockholders of the Company, contingent upon the reporting person's continued service as a member of the Company's board of directors through such time."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents a grant of restricted stock units (\"RSUs\"). The RSUs vest on the earlier of the one-year anniversary of the grant and the date of the 2026 Annual Meeting of Stockholders of the Company, contingent upon the reporting person's continued service as a member of the Company's board of directors through such time."},{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F1","text":"Represents a grant of restricted stock units (\"RSUs\"). The RSUs vest on the earlier of the one-year anniversary of the grant and the date of the 2026 Annual Meeting of Stockholders of the Company, contingent upon the reporting person's continued service as a member of the Company's board of directors through such time."}],"balance_after":5994820,"source":{"system":"sec-edgar","filing":"0001628280-25-032141","document":"wk-form4_1750278831.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818093/000162828025032141/wk-form4_1750278831.xml","form_type":"4"}},{"id":1133598,"issuer":{"id":3756,"kind":"organization","name":"Bausch & Lomb Corp"},"owners":[{"id":11572,"kind":"person","name":"SAUNDERS BRENT L","position":1,"cik":"0001268854","reported_name":"SAUNDERS BRENT L","relationship":{"director":true,"officer":true,"officer_title":"CEO and Chairman of the Board"}}],"security":"Common Shares, No Par Value","published_at":"2025-05-27T12:16:24.000Z","date":"2025-05-22","kind":"grant","planned":false,"acquired":true,"shares":22000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents matching restricted share units (\"MRSUs\") granted to the reporting person in connection with the open market purchase of common shares reported on Table I above, pursuant to the issuer's matching share program. One-third of the MRSUs will vest on each of the first, second, and third anniversaries following the date of grant, subject to the reporting person's continued service (except in limited circumstances)."}],"balance_after":741156,"source":{"system":"sec-edgar","filing":"0001127602-25-015582","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1860742/000112760225015582/form4.xml","form_type":"4"}},{"id":1133597,"issuer":{"id":3756,"kind":"organization","name":"Bausch & Lomb Corp"},"owners":[{"id":11572,"kind":"person","name":"SAUNDERS BRENT L","position":1,"cik":"0001268854","reported_name":"SAUNDERS BRENT L","relationship":{"director":true,"officer":true,"officer_title":"CEO and Chairman of the Board"}}],"security":"Common Shares, No Par Value","published_at":"2025-05-27T12:16:24.000Z","date":"2025-05-22","kind":"purchase","planned":false,"acquired":true,"shares":22000,"price":11.276,"value":248072.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Weighted average price. These shares were purchased in multiple transactions at prices ranging from $11.19 to $11.38 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above."}],"balance_after":719156,"source":{"system":"sec-edgar","filing":"0001127602-25-015582","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1860742/000112760225015582/form4.xml","form_type":"4"}},{"id":1137194,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":11572,"kind":"person","name":"SAUNDERS BRENT L","position":1,"cik":"0001268854","reported_name":"SAUNDERS BRENT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-22T21:00:11.000Z","date":"2025-05-20","kind":"exercise","planned":false,"acquired":false,"shares":120000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Immediately exercisable."}],"balance_after":470950,"derivative":{"exercise_price":1.01,"expiration_date":"2031-06-15","underlying":"Common Stock","underlying_shares":120000},"source":{"system":"sec-edgar","filing":"0001415889-25-014185","document":"form4-05222025_050503.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588925014185/form4-05222025_050503.xml","form_type":"4"}},{"id":1137193,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":11572,"kind":"person","name":"SAUNDERS BRENT L","position":1,"cik":"0001268854","reported_name":"SAUNDERS BRENT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-05-22T21:00:11.000Z","date":"2025-05-20","kind":"sale","planned":false,"acquired":false,"shares":120000,"price":14.2502,"value":1710024.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The weighted average sale price for the transaction reported was $14.2502 and the range of prices were between $14.25 and $14.26. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001415889-25-014185","document":"form4-05222025_050503.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588925014185/form4-05222025_050503.xml","form_type":"4"}},{"id":1137192,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":11572,"kind":"person","name":"SAUNDERS BRENT L","position":1,"cik":"0001268854","reported_name":"SAUNDERS BRENT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-05-22T21:00:11.000Z","date":"2025-05-20","kind":"exercise","planned":false,"acquired":true,"shares":120000,"price":1.01,"value":121200.0,"ownership":{"direct":true},"balance_after":120000,"source":{"system":"sec-edgar","filing":"0001415889-25-014185","document":"form4-05222025_050503.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588925014185/form4-05222025_050503.xml","form_type":"4"}},{"id":1238705,"issuer":{"id":3756,"kind":"organization","name":"Bausch & Lomb Corp"},"owners":[{"id":11572,"kind":"person","name":"SAUNDERS BRENT L","position":1,"cik":"0001268854","reported_name":"SAUNDERS BRENT L","relationship":{"director":true,"officer":true,"officer_title":"CEO and Chairman of the Board"}}],"security":"Non-Qualified Stock Options (right to purchase)","published_at":"2025-02-28T21:23:50.000Z","date":"2025-02-26","kind":"grant","planned":false,"acquired":true,"shares":600858,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Reflects the grant of stock options to purchase common shares under the Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock options are generally scheduled to vest and become exercisable in equal installments on each of the first three anniversaries of the grant date, subject to the terms of the applicable award agreement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The stock options will expire on the tenth anniversary of the grant date."}],"balance_after":600858,"derivative":{"exercise_price":15.86,"underlying":"Common Shares, No Par Value","underlying_shares":600858},"source":{"system":"sec-edgar","filing":"0001127602-25-007260","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1860742/000112760225007260/form4.xml","form_type":"4"}},{"id":1238704,"issuer":{"id":3756,"kind":"organization","name":"Bausch & Lomb Corp"},"owners":[{"id":11572,"kind":"person","name":"SAUNDERS BRENT L","position":1,"cik":"0001268854","reported_name":"SAUNDERS BRENT L","relationship":{"director":true,"officer":true,"officer_title":"CEO and Chairman of the Board"}}],"security":"Common Shares, No Par Value","published_at":"2025-02-28T21:23:50.000Z","date":"2025-02-26","kind":"grant","planned":false,"acquired":true,"shares":168168,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects the grant of restricted stock units (\"RSUs\") under the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan (as amended and restated, the \"Plan\") which are scheduled to vest one-third on each of the first three anniversaries of the date of grant, subject generally to the reporting person's continued service and the terms of the Plan and the applicable award agreement thereunder. Vested RSUs are settled in common shares, no par value, of Bausch + Lomb Corporation."}],"balance_after":697156,"source":{"system":"sec-edgar","filing":"0001127602-25-007260","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1860742/000112760225007260/form4.xml","form_type":"4"}},{"id":1321814,"issuer":{"id":3756,"kind":"organization","name":"Bausch & Lomb Corp"},"owners":[{"id":11572,"kind":"person","name":"SAUNDERS BRENT L","position":1,"cik":"0001268854","reported_name":"SAUNDERS BRENT L","relationship":{"director":true,"officer":true,"officer_title":"CEO and Chairman of the Board"}}],"security":"Common Shares, No Par Value","published_at":"2024-12-26T21:18:43.000Z","date":"2024-12-23","kind":"tax_withholding","planned":false,"acquired":false,"shares":24649,"price":17.83,"value":439491.67,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This number represents common shares withheld to satisfy the tax withholding obligations due upon vesting of restricted share units."}],"balance_after":528988,"source":{"system":"sec-edgar","filing":"0001127602-24-030056","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1860742/000112760224030056/form4.xml","form_type":"4"}},{"id":1321813,"issuer":{"id":3756,"kind":"organization","name":"Bausch & Lomb Corp"},"owners":[{"id":11572,"kind":"person","name":"SAUNDERS BRENT L","position":1,"cik":"0001268854","reported_name":"SAUNDERS BRENT L","relationship":{"director":true,"officer":true,"officer_title":"CEO and Chairman of the Board"}}],"security":"Common Shares, No Par Value","published_at":"2024-12-26T21:18:43.000Z","date":"2024-12-23","kind":"tax_withholding","planned":false,"acquired":false,"shares":73782,"price":17.83,"value":1315533.06,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This number represents common shares withheld to satisfy the tax withholding obligations due upon vesting of restricted share units."}],"balance_after":553637,"source":{"system":"sec-edgar","filing":"0001127602-24-030056","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1860742/000112760224030056/form4.xml","form_type":"4"}},{"id":1435389,"issuer":{"id":6863,"kind":"organization","name":"SkinHealth Systems Inc.","symbol":"SKIN"},"owners":[{"id":11572,"kind":"person","name":"SAUNDERS BRENT L","position":1,"cik":"0001268854","reported_name":"SAUNDERS BRENT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Chairman"}}],"security":"Class A Common Stock","published_at":"2024-08-13T21:00:11.000Z","date":"2024-08-12","kind":"purchase","planned":false,"acquired":true,"shares":40450,"price":1.08,"value":43686.0,"ownership":{"direct":true},"balance_after":5921769,"source":{"system":"sec-edgar","filing":"0001628280-24-036967","document":"wk-form4_1723582804.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818093/000162828024036967/wk-form4_1723582804.xml","form_type":"4"}},{"id":1438907,"issuer":{"id":3756,"kind":"organization","name":"Bausch & Lomb Corp"},"owners":[{"id":11572,"kind":"person","name":"SAUNDERS BRENT L","position":1,"cik":"0001268854","reported_name":"SAUNDERS BRENT L","relationship":{"director":true,"officer":true,"officer_title":"CEO and Chairman of the Board"}}],"security":"Common Shares, No Par Value","published_at":"2024-08-07T21:29:48.000Z","date":"2024-08-05","kind":"grant","planned":false,"acquired":true,"shares":32250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents matching Restricted Share Units (\"MRSUs\") granted to the Reporting Person in connection with the open market purchase of Common Shares reported on Table I above, pursuant to the Issuer's Matching Share Program. One-third of the MRSUs will vest on each of the first, second, and third anniversaries following the date of grant, subject to the Reporting Person's continued service (except in limited circumstances)."}],"balance_after":627419,"source":{"system":"sec-edgar","filing":"0001127602-24-021823","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1860742/000112760224021823/form4.xml","form_type":"4"}},{"id":1438906,"issuer":{"id":3756,"kind":"organization","name":"Bausch & Lomb Corp"},"owners":[{"id":11572,"kind":"person","name":"SAUNDERS BRENT L","position":1,"cik":"0001268854","reported_name":"SAUNDERS BRENT L","relationship":{"director":true,"officer":true,"officer_title":"CEO and Chairman of the Board"}}],"security":"Common Shares, No Par Value","published_at":"2024-08-07T21:29:48.000Z","date":"2024-08-05","kind":"purchase","planned":false,"acquired":true,"shares":32250,"price":15.661,"value":505067.25,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Weighted average price. These shares were purchased in multiple transactions at prices ranging from $15.395 to $15.8 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above."}],"balance_after":595169,"source":{"system":"sec-edgar","filing":"0001127602-24-021823","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1860742/000112760224021823/form4.xml","form_type":"4"}},{"id":1457164,"issuer":{"id":6863,"kind":"organization","name":"SkinHealth Systems Inc.","symbol":"SKIN"},"owners":[{"id":11572,"kind":"person","name":"SAUNDERS BRENT L","position":1,"cik":"0001268854","reported_name":"SAUNDERS BRENT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Chairman"}}],"security":"Class A Common Stock","published_at":"2024-07-10T20:32:44.000Z","date":"2024-07-08","kind":"grant","planned":false,"acquired":true,"shares":78534,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents a grant of restricted stock units (\"RSUs\"). The RSUs vest on the earlier of the one-year anniversary of the grant and the date of the 2025 Annual Meeting of Stockholders of the Company, contingent upon the reporting person's continued service as a member of the Company's board of directors through such time."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a grant of restricted stock units (\"RSUs\"). The RSUs vest on the earlier of the one-year anniversary of the grant and the date of the 2025 Annual Meeting of Stockholders of the Company, contingent upon the reporting person's continued service as a member of the Company's board of directors through such time."},{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F2","text":"Represents a grant of restricted stock units (\"RSUs\"). The RSUs vest on the earlier of the one-year anniversary of the grant and the date of the 2025 Annual Meeting of Stockholders of the Company, contingent upon the reporting person's continued service as a member of the Company's board of directors through such time."}],"balance_after":5881319,"source":{"system":"sec-edgar","filing":"0001628280-24-031586","document":"wk-form4_1720643557.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1818093/000162828024031586/wk-form4_1720643557.xml","form_type":"4"}},{"id":1457163,"issuer":{"id":6863,"kind":"organization","name":"SkinHealth Systems Inc.","symbol":"SKIN"},"owners":[{"id":11572,"kind":"person","name":"SAUNDERS BRENT L","position":1,"cik":"0001268854","reported_name":"SAUNDERS BRENT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Chairman"}}],"security":"Class A Common Stock","published_at":"2024-07-10T20:32:44.000Z","date":"2023-02-03","kind":"tax_withholding","planned":false,"acquired":false,"shares":13548,"price":12.9,"value":174769.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares withheld by the issuer to satisfy tax withholding requirements on vesting of restricted stock units and does not represent a sale."}],"balance_after":5802785,"source":{"system":"sec-edgar","filing":"0001628280-24-031586","document":"wk-form4_1720643557.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1818093/000162828024031586/wk-form4_1720643557.xml","form_type":"4"}},{"id":1457162,"issuer":{"id":6863,"kind":"organization","name":"SkinHealth Systems Inc.","symbol":"SKIN"},"owners":[{"id":11572,"kind":"person","name":"SAUNDERS BRENT L","position":1,"cik":"0001268854","reported_name":"SAUNDERS BRENT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Chairman"}}],"security":"Class A Common Stock","published_at":"2024-07-10T20:32:44.000Z","date":"2022-12-30","kind":"tax_withholding","planned":false,"acquired":false,"shares":2167,"price":9.1,"value":19719.7,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares withheld by the issuer to satisfy tax withholding requirements on vesting of restricted stock units and does not represent a sale."}],"balance_after":5816333,"source":{"system":"sec-edgar","filing":"0001628280-24-031586","document":"wk-form4_1720643557.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1818093/000162828024031586/wk-form4_1720643557.xml","form_type":"4"}},{"id":1457161,"issuer":{"id":6863,"kind":"organization","name":"SkinHealth Systems Inc.","symbol":"SKIN"},"owners":[{"id":11572,"kind":"person","name":"SAUNDERS BRENT L","position":1,"cik":"0001268854","reported_name":"SAUNDERS BRENT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Chairman"}}],"security":"Class A Common Stock","published_at":"2024-07-10T20:32:44.000Z","date":"2022-09-30","kind":"tax_withholding","planned":false,"acquired":false,"shares":2166,"price":11.79,"value":25537.14,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares withheld by the issuer to satisfy tax withholding requirements on vesting of restricted stock units and does not represent a sale."}],"balance_after":5818500,"source":{"system":"sec-edgar","filing":"0001628280-24-031586","document":"wk-form4_1720643557.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1818093/000162828024031586/wk-form4_1720643557.xml","form_type":"4"}},{"id":1457160,"issuer":{"id":6863,"kind":"organization","name":"SkinHealth Systems Inc.","symbol":"SKIN"},"owners":[{"id":11572,"kind":"person","name":"SAUNDERS BRENT L","position":1,"cik":"0001268854","reported_name":"SAUNDERS BRENT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Chairman"}}],"security":"Class A Common Stock","published_at":"2024-07-10T20:32:44.000Z","date":"2022-06-30","kind":"tax_withholding","planned":false,"acquired":false,"shares":3076,"price":12.86,"value":39557.36,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares withheld by the issuer to satisfy tax withholding requirements on vesting of restricted stock units and does not represent a sale."}],"balance_after":5820666,"source":{"system":"sec-edgar","filing":"0001628280-24-031586","document":"wk-form4_1720643557.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818093/000162828024031586/wk-form4_1720643557.xml","form_type":"4"}},{"id":1457159,"issuer":{"id":6863,"kind":"organization","name":"SkinHealth Systems Inc.","symbol":"SKIN"},"owners":[{"id":11572,"kind":"person","name":"SAUNDERS BRENT L","position":1,"cik":"0001268854","reported_name":"SAUNDERS BRENT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Chairman"}}],"security":"Class A Common Stock","published_at":"2024-07-10T20:32:44.000Z","date":"2022-03-31","kind":"tax_withholding","planned":false,"acquired":false,"shares":3711,"price":16.88,"value":62641.68,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares withheld by the issuer to satisfy tax withholding requirements on vesting of restricted stock units and does not represent a sale."}],"balance_after":5823742,"source":{"system":"sec-edgar","filing":"0001628280-24-031586","document":"wk-form4_1720643557.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818093/000162828024031586/wk-form4_1720643557.xml","form_type":"4"}},{"id":1470696,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":11572,"kind":"person","name":"SAUNDERS BRENT L","position":1,"cik":"0001268854","reported_name":"SAUNDERS BRENT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-24T21:00:07.000Z","date":"2024-06-20","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest in full on the earlier of June 20, 2025 or the date of the Issuer's 2025 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors."}],"balance_after":40000,"derivative":{"exercise_price":7.73,"expiration_date":"2034-06-19","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001415889-24-018010","document":"form4-06242024_050602.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588924018010/form4-06242024_050602.xml","form_type":"4"}},{"id":1607509,"issuer":{"id":3756,"kind":"organization","name":"Bausch & Lomb Corp"},"owners":[{"id":11572,"kind":"person","name":"SAUNDERS BRENT L","position":1,"cik":"0001268854","reported_name":"SAUNDERS BRENT L","relationship":{"director":true,"officer":true,"officer_title":"CEO and Chair"}}],"security":"Non-Qualified Stock Options (right to purchase)","published_at":"2024-03-01T21:26:42.000Z","date":"2024-02-28","kind":"grant","planned":false,"acquired":true,"shares":569105,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Reflects the grant of stock options to purchase common shares under the Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock options are generally scheduled to vest and become exercisable in equal installments on each of the first three anniversaries of the grant date, subject to the terms of the applicable award agreement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The stock options will expire on the tenth anniversary of the grant date."}],"balance_after":569105,"derivative":{"exercise_price":16.85,"underlying":"Common Shares, No Par Value","underlying_shares":569105},"source":{"system":"sec-edgar","filing":"0001127602-24-007883","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1860742/000112760224007883/form4.xml","form_type":"4"}},{"id":1607508,"issuer":{"id":3756,"kind":"organization","name":"Bausch & Lomb Corp"},"owners":[{"id":11572,"kind":"person","name":"SAUNDERS BRENT L","position":1,"cik":"0001268854","reported_name":"SAUNDERS BRENT L","relationship":{"director":true,"officer":true,"officer_title":"CEO and Chair"}}],"security":"Common Shares, No Par Value","published_at":"2024-03-01T21:26:42.000Z","date":"2024-02-28","kind":"grant","planned":false,"acquired":true,"shares":187919,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects the grant of restricted stock units (\"RSUs\") under the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan (as amended and restated, the \"Plan\") which are scheduled to vest one-third on each of the first three anniversaries of the date of grant, subject generally to the reporting person's continued service and the terms of the Plan and the applicable award agreement thereunder. Vested RSUs are settled in common shares, no par value, of Bausch + Lomb Corporation."}],"balance_after":562919,"source":{"system":"sec-edgar","filing":"0001127602-24-007883","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1860742/000112760224007883/form4.xml","form_type":"4"}},{"id":1804710,"issuer":{"id":6863,"kind":"organization","name":"SkinHealth Systems Inc.","symbol":"SKIN"},"owners":[{"id":11572,"kind":"person","name":"SAUNDERS BRENT L","position":1,"cik":"0001268854","reported_name":"SAUNDERS BRENT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Chairman"}}],"security":"Class A Common Stock","published_at":"2023-08-17T21:11:36.000Z","date":"2023-08-16","kind":"purchase","planned":false,"acquired":true,"shares":59380,"price":6.1026,"value":362372.388,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.04 to $6.15, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":5827453,"source":{"system":"sec-edgar","filing":"0001628280-23-029854","document":"wk-form4_1692306684.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818093/000162828023029854/wk-form4_1692306684.xml","form_type":"4"}},{"id":1842701,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":11572,"kind":"person","name":"SAUNDERS BRENT L","position":1,"cik":"0001268854","reported_name":"SAUNDERS BRENT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-29T01:00:29.000Z","date":"2023-06-27","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest in full on the earlier of June 27, 2024 or the date of the Issuer's 2024 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors."}],"balance_after":40000,"derivative":{"exercise_price":6.5,"expiration_date":"2033-06-26","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001209191-23-040109","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000120919123040109/doc4.xml","form_type":"4"}},{"id":1853447,"issuer":{"id":6863,"kind":"organization","name":"SkinHealth Systems Inc.","symbol":"SKIN"},"owners":[{"id":11572,"kind":"person","name":"SAUNDERS BRENT L","position":1,"cik":"0001268854","reported_name":"SAUNDERS BRENT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Chairman"}}],"security":"Class A Common Stock","published_at":"2023-06-16T21:16:24.000Z","date":"2023-06-14","kind":"grant","planned":false,"acquired":true,"shares":16357,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a grant of restricted stock units (\"RSUs\"). The RSUs vest on the earlier of the one-year anniversary of the grant and the date of the 2024 Annual Meeting of Stockholders of the Company, contingent upon the reporting person's continued service as a member of the Company's board of directors through such time."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents a grant of restricted stock units (\"RSUs\"). The RSUs vest on the earlier of the one-year anniversary of the grant and the date of the 2024 Annual Meeting of Stockholders of the Company, contingent upon the reporting person's continued service as a member of the Company's board of directors through such time."},{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F1","text":"Represents a grant of restricted stock units (\"RSUs\"). The RSUs vest on the earlier of the one-year anniversary of the grant and the date of the 2024 Annual Meeting of Stockholders of the Company, contingent upon the reporting person's continued service as a member of the Company's board of directors through such time."}],"balance_after":5768073,"source":{"system":"sec-edgar","filing":"0001628280-23-022509","document":"wk-form4_1686950173.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818093/000162828023022509/wk-form4_1686950173.xml","form_type":"4"}},{"id":60786,"issuer":{"id":2802,"kind":"organization","name":"CISCO SYSTEMS, INC.","symbol":"CSCO"},"owners":[{"id":11572,"kind":"person","name":"SAUNDERS BRENT L","position":1,"cik":"0001268854","reported_name":"SAUNDERS BRENT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-12-12T23:43:35.000Z","date":"2022-12-08","kind":"grant","acquired":true,"shares":5001,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a fully vested deferred restricted stock unit award covering shares which will settle in shares on, or as soon as practicable after, the reporting person's \"separation from service\" to Cisco within the meaning of Section 409A of the Internal Revenue Code."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 1,751 dividend equivalents accrued on vested deferred restricted stock units. Each dividend equivalent is the economic equivalent of one share of Cisco common stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Since the reporting person's last Form 4 filing, the reporting person transferred 12,768 shares relating to vested deferred restricted stock units and 1,264 dividend equivalents accrued on vested deferred restricted stock units previously reported as held directly by the reporting person in a transaction exempt from reporting under Section 16(a) of the Exchange Act, and such shares are no longer beneficially owned by the reporting person."}],"balance_after":24143,"source":{"system":"sec-edgar","filing":"0001209191-22-060763","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/858877/000120919122060763/doc4.xml","form_type":"4"}},{"id":2120034,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":11572,"kind":"person","name":"SAUNDERS BRENT L","position":1,"cik":"0001268854","reported_name":"SAUNDERS BRENT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2022-11-10T23:00:24.000Z","date":"2022-11-08","kind":"grant","acquired":true,"shares":153647,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Under the terms of the Merger Agreement, on November 8, 2022, Merger Sub merged with and into ARS (the \"Merger\"), with ARS surviving the Merger as a wholly-owned subsidiary of the Issuer.  Upon the closing of the Merger, each outstanding option to purchase shares of ARS common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Silverback Therapeutics, Inc. to ARS Pharmaceuticals, Inc."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Received in exchange for a stock option to acquire 130,000 shares of common stock of ARS with the exercise price of $1.19 per share pursuant to the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the option vest on the one year anniversary of the vesting commencement date and the balance of the shares vest in a series of thirty-six (36) successive equal monthly installments measured from the first anniversary of the vesting commencement date."}],"balance_after":153647,"derivative":{"exercise_price":1.01,"expiration_date":"2031-06-15","underlying":"Common Stock","underlying_shares":153647},"source":{"system":"sec-edgar","filing":"0001209191-22-056441","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000120919122056441/doc4.xml","form_type":"4"}},{"id":2120033,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":11572,"kind":"person","name":"SAUNDERS BRENT L","position":1,"cik":"0001268854","reported_name":"SAUNDERS BRENT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2022-11-10T23:00:24.000Z","date":"2022-11-08","kind":"grant","acquired":true,"shares":590950,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Received in exchange for a stock option to acquire 500,000 shares of common stock of ARS Pharmaceuticals, Inc. (\"ARS\") with the exercise price of $1.19 per share pursuant to an Agreement and Plan of Merger and Reorganization by and among ARS, the Issuer and Sabre Merger Sub, Inc., a wholly-owned subsidiary of the Issuer (\"Merger Sub\"), as amended (the \"Merger Agreement\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Under the terms of the Merger Agreement, on November 8, 2022, Merger Sub merged with and into ARS (the \"Merger\"), with ARS surviving the Merger as a wholly-owned subsidiary of the Issuer.  Upon the closing of the Merger, each outstanding option to purchase shares of ARS common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Silverback Therapeutics, Inc. to ARS Pharmaceuticals, Inc."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the option vest on the one year anniversary of the vesting commencement date and the balance of the shares vest in a series of thirty-six (36) successive equal monthly installments measured from the first anniversary of the vesting commencement date."}],"balance_after":590950,"derivative":{"exercise_price":1.01,"expiration_date":"2031-06-15","underlying":"Common Stock","underlying_shares":590950},"source":{"system":"sec-edgar","filing":"0001209191-22-056441","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000120919122056441/doc4.xml","form_type":"4"}},{"id":2222115,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":11572,"kind":"person","name":"SAUNDERS BRENT L","position":1,"cik":"0001268854","reported_name":"SAUNDERS BRENT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-24T20:35:21.000Z","date":"2022-06-22","kind":"grant","acquired":true,"shares":104921,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/3rd of the shares underlying the option will vest on June 22, 2023; thereafter, 1/3rd of the remaining underlying shares will vest on an annual basis, so that all of the underlying shares will be vested on the June 22, 2025, subject to the optionee's continued service on the Board of Directors of the Company."}],"balance_after":104921,"derivative":{"exercise_price":8.45,"expiration_date":"2032-06-22","underlying":"Common Stock","underlying_shares":104921},"source":{"system":"sec-edgar","filing":"0001209191-22-039264","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000120919122039264/doc4.xml","form_type":"4"}},{"id":2409250,"issuer":{"id":6863,"kind":"organization","name":"SkinHealth Systems Inc.","symbol":"SKIN"},"owners":[{"id":11572,"kind":"person","name":"SAUNDERS BRENT L","position":1,"cik":"0001268854","reported_name":"SAUNDERS BRENT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Executive Chairman"}}],"security":"Class A Common Stock","published_at":"2022-02-09T01:16:44.000Z","date":"2022-02-04","kind":"grant","acquired":true,"shares":158450,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents a grant of restricted stock units that vest in one-third increments on each of the first three anniversaries of the grant date of February 4, 2022, in each case subject to continued service through the vesting date and certain acceleration rights."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a grant of restricted stock units that vest in one-third increments on each of the first three anniversaries of the grant date of February 4, 2022, in each case subject to continued service through the vesting date and certain acceleration rights."}],"balance_after":5751716,"source":{"system":"sec-edgar","filing":"0001818093-22-000031","document":"wf-form4_164436938991494.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818093/000181809322000031/wf-form4_164436938991494.xml","form_type":"4"}},{"id":2409249,"issuer":{"id":6863,"kind":"organization","name":"SkinHealth Systems Inc.","symbol":"SKIN"},"owners":[{"id":11572,"kind":"person","name":"SAUNDERS BRENT L","position":1,"cik":"0001268854","reported_name":"SAUNDERS BRENT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Executive Chairman"}}],"security":"Class A Common Stock","published_at":"2022-02-09T01:16:44.000Z","date":"2022-02-04","kind":"grant","acquired":true,"shares":35581,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a grant of restricted stock units that vest in 25% increments on each of March 31, 2022, June 30, 2022, September 30, 2022 and December 31, 2022, in each case subject to continued service through the vesting date and certain acceleration rights."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents a grant of restricted stock units that vest in 25% increments on each of March 31, 2022, June 30, 2022, September 30, 2022 and December 31, 2022, in each case subject to continued service through the vesting date and certain acceleration rights."}],"balance_after":5593266,"source":{"system":"sec-edgar","filing":"0001818093-22-000031","document":"wf-form4_164436938991494.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818093/000181809322000031/wf-form4_164436938991494.xml","form_type":"4"}},{"id":2421714,"issuer":{"id":6863,"kind":"organization","name":"SkinHealth Systems Inc.","symbol":"SKIN"},"owners":[{"id":11572,"kind":"person","name":"SAUNDERS BRENT L","position":1,"cik":"0001268854","reported_name":"SAUNDERS BRENT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Executive Chairman"}}],"security":"Class A Common Stock","published_at":"2022-01-31T17:31:16.000Z","date":"2022-01-27","kind":"tax_withholding","acquired":false,"shares":6812,"price":12.24,"value":83378.88,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On December 31, 2021, 30,963 restricted stock units vested in full. All of the shares reported as disposed of in this Form 4 represents the number of shares of Class A Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of the restricted stock units and does not represent a sale."}],"balance_after":5557685,"source":{"system":"sec-edgar","filing":"0001818093-22-000021","document":"wf-form4_164365026176711.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818093/000181809322000021/wf-form4_164365026176711.xml","form_type":"4"}},{"id":2454431,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":11572,"kind":"person","name":"SAUNDERS BRENT L","position":1,"cik":"0001268854","reported_name":"SAUNDERS BRENT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-01-04T00:59:33.000Z","date":"2021-12-29","kind":"purchase","acquired":true,"shares":17600,"price":14.4818,"value":254879.68,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the weighted average purchase price of the shares purchased from $14.45 to $14.49 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions as reported in this footnote."}],"balance_after":17600,"source":{"system":"sec-edgar","filing":"0000899243-22-000193","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924322000193/doc4.xml","form_type":"4"}},{"id":74283,"issuer":{"id":2802,"kind":"organization","name":"CISCO SYSTEMS, INC.","symbol":"CSCO"},"owners":[{"id":11572,"kind":"person","name":"SAUNDERS BRENT L","position":1,"cik":"0001268854","reported_name":"SAUNDERS BRENT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-12-16T01:07:42.000Z","date":"2021-12-13","kind":"grant","acquired":true,"shares":4180,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a fully vested deferred restricted stock unit award covering shares which will settle in shares on, or as soon as practicable after, the reporting person's \"separation from service\" to Cisco within the meaning of Section 409A of the Internal Revenue Code."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 2,344 dividend equivalents accrued on vested deferred restricted stock units.  Each dividend equivalent is the economic equivalent of one share of Cisco common stock."}],"balance_after":32503,"source":{"system":"sec-edgar","filing":"0001209191-21-069855","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/858877/000120919121069855/doc4.xml","form_type":"4"}},{"id":2571479,"issuer":{"id":6863,"kind":"organization","name":"SkinHealth Systems Inc.","symbol":"SKIN"},"owners":[{"id":11572,"kind":"person","name":"SAUNDERS BRENT L","position":1,"cik":"0001268854","reported_name":"SAUNDERS BRENT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Executive Chairman"}}],"security":"Performance Restricted Stock Units","published_at":"2021-09-14T23:53:28.000Z","date":"2021-09-10","kind":"grant","acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Represents an award of performance-based restricted stock units that may be earned over a four-year performance period based on the achievement of performance goals related to the Company's stock price and continued employment with the Company through the end of the performance period. Each performance restricted stock unit converts on a one-for-one basis to Class A Common Stock upon vesting."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents an award of performance-based restricted stock units that may be earned over a four-year performance period based on the achievement of performance goals related to the Company's stock price and continued employment with the Company through the end of the performance period. Each performance restricted stock unit converts on a one-for-one basis to Class A Common Stock upon vesting."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Represents an award of performance-based restricted stock units that may be earned over a four-year performance period based on the achievement of performance goals related to the Company's stock price and continued employment with the Company through the end of the performance period. Each performance restricted stock unit converts on a one-for-one basis to Class A Common Stock upon vesting."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Represents an award of performance-based restricted stock units that may be earned over a four-year performance period based on the achievement of performance goals related to the Company's stock price and continued employment with the Company through the end of the performance period. Each performance restricted stock unit converts on a one-for-one basis to Class A Common Stock upon vesting."}],"balance_after":60000,"derivative":{"underlying":"Class A Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001818093-21-000067","document":"wf-form4_163166358942566.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1818093/000181809321000067/wf-form4_163166358942566.xml","form_type":"4"}},{"id":2571478,"issuer":{"id":6863,"kind":"organization","name":"SkinHealth Systems Inc.","symbol":"SKIN"},"owners":[{"id":11572,"kind":"person","name":"SAUNDERS BRENT L","position":1,"cik":"0001268854","reported_name":"SAUNDERS BRENT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Executive Chairman"}}],"security":"Class A Common Stock","published_at":"2021-09-14T23:53:28.000Z","date":"2021-09-10","kind":"grant","acquired":true,"shares":30963,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents restricted stock units (the \"RSUs\") granted in lieu of annual cash salary and bonus for 2021.  The RSUs will vest in full on December 31, 2021, subject to continued service with the Company."}],"balance_after":5564497,"source":{"system":"sec-edgar","filing":"0001818093-21-000067","document":"wf-form4_163166358942566.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818093/000181809321000067/wf-form4_163166358942566.xml","form_type":"4"}},{"id":2658956,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":11572,"kind":"person","name":"SAUNDERS BRENT L","position":1,"cik":"0001268854","reported_name":"SAUNDERS BRENT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-22T23:08:08.000Z","date":"2021-06-17","kind":"grant","acquired":true,"shares":38895,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests and becomes exercisable in three annual installments after June 17, 2021, subject to the Reporting Person's continued service on the Issuer's Board of Directors through each such date."}],"balance_after":38895,"derivative":{"exercise_price":62.63,"expiration_date":"2031-06-16","underlying":"Common Stock","underlying_shares":38895},"source":{"system":"sec-edgar","filing":"0000899243-21-025387","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924321025387/doc4.xml","form_type":"4"}},{"id":2709376,"issuer":{"id":6863,"kind":"organization","name":"SkinHealth Systems Inc.","symbol":"SKIN"},"owners":[{"id":11572,"kind":"person","name":"SAUNDERS BRENT L","position":1,"cik":"0001268854","reported_name":"SAUNDERS BRENT L","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"Executive Chairman"}}],"security":"Warrant (right to buy)","published_at":"2021-05-19T01:22:28.000Z","date":"2021-05-14","kind":"other","acquired":false,"shares":9333333,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By BLS"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a distribution for no consideration by BLS Investor Group LLC (\"BLS\") to its members in accordance with their respective interests. The reporting person is the managing member of BLS and may be deemed to beneficially own the shares held by BLS, but disclaims beneficial ownership of such securities except to any pecuniary interest he may have therein."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The warrants are exercisable by the holder into shares of Class A Common Stock on a one-for-one basis commencing on 10/2/2021, and expire on 5/4/26 or earlier redemption or liquidation."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The warrants are exercisable by the holder into shares of Class A Common Stock on a one-for-one basis commencing on 10/2/2021, and expire on 5/4/26 or earlier redemption or liquidation."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"Represents a distribution for no consideration by BLS Investor Group LLC (\"BLS\") to its members in accordance with their respective interests. The reporting person is the managing member of BLS and may be deemed to beneficially own the shares held by BLS, but disclaims beneficial ownership of such securities except to any pecuniary interest he may have therein."}],"balance_after":0,"derivative":{"exercise_price":11.5,"underlying":"Class A Common Stock","underlying_shares":9333333},"source":{"system":"sec-edgar","filing":"0001818093-21-000010","document":"wf-form4_162138732027201.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1818093/000181809321000010/wf-form4_162138732027201.xml","form_type":"4"}},{"id":2709375,"issuer":{"id":6863,"kind":"organization","name":"SkinHealth Systems Inc.","symbol":"SKIN"},"owners":[{"id":11572,"kind":"person","name":"SAUNDERS BRENT L","position":1,"cik":"0001268854","reported_name":"SAUNDERS BRENT L","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"Executive Chairman"}}],"security":"Class A Common Stock","published_at":"2021-05-19T01:22:28.000Z","date":"2021-05-14","kind":"other","acquired":false,"shares":11500000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By BLS"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a distribution for no consideration by BLS Investor Group LLC (\"BLS\") to its members in accordance with their respective interests. The reporting person is the managing member of BLS and may be deemed to beneficially own the shares held by BLS, but disclaims beneficial ownership of such securities except to any pecuniary interest he may have therein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"Represents a distribution for no consideration by BLS Investor Group LLC (\"BLS\") to its members in accordance with their respective interests. The reporting person is the managing member of BLS and may be deemed to beneficially own the shares held by BLS, but disclaims beneficial ownership of such securities except to any pecuniary interest he may have therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001818093-21-000010","document":"wf-form4_162138732027201.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818093/000181809321000010/wf-form4_162138732027201.xml","form_type":"4"}},{"id":2709374,"issuer":{"id":6863,"kind":"organization","name":"SkinHealth Systems Inc.","symbol":"SKIN"},"owners":[{"id":11572,"kind":"person","name":"SAUNDERS BRENT L","position":1,"cik":"0001268854","reported_name":"SAUNDERS BRENT L","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"Executive Chairman"}},{"id":139327,"kind":"organization","name":"BLS Investor Group LLC","position":2,"cik":"0001818155","reported_name":"BLS Investor Group LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (right to buy)","published_at":"2021-05-19T01:14:20.000Z","date":"2020-10-02","kind":"grant","acquired":true,"shares":9333333,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By BLS"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents warrants to purchase Class A Common Stock issued to BLS Investor Group LLC (\"BLS\") in connection with the Issuer's initial public offering pursuant to the Registration Statement on Form S-1, as amended and filed with the SEC on September 21, 2020 (the \"Registration Statement\"). Brenton L. Saunders is the managing member of BLS and may be deemed to beneficially own the shares held by BLS.  Mr. Saunders disclaims beneficial ownership of such securities except to any pecuniary interest he may have therein."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Represents warrants to purchase Class A Common Stock issued to BLS Investor Group LLC (\"BLS\") in connection with the Issuer's initial public offering pursuant to the Registration Statement on Form S-1, as amended and filed with the SEC on September 21, 2020 (the \"Registration Statement\"). Brenton L. Saunders is the managing member of BLS and may be deemed to beneficially own the shares held by BLS.  Mr. Saunders disclaims beneficial ownership of such securities except to any pecuniary interest he may have therein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The warrants are exercisable by the holder into shares of Class A Common Stock on a one-for-one basis commencing on the later of 12 months from the closing of the IPO or 30 days after the completion of our initial business combination, and expire five years after the completion of our initial business combination or earlier upon redemption or liquidation, each as described in the Registration Statement."}],"balance_after":9333333,"derivative":{"exercise_price":11.5,"underlying":"Class A Common Stock","underlying_shares":9333333},"source":{"system":"sec-edgar","filing":"0001818093-21-000009","document":"wf-form4_162138684705746.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818093/000181809321000009/wf-form4_162138684705746.xml","form_type":"4"}},{"id":2721867,"issuer":{"id":6863,"kind":"organization","name":"SkinHealth Systems Inc.","symbol":"SKIN"},"owners":[{"id":11572,"kind":"person","name":"SAUNDERS BRENT L","position":1,"cik":"0001268854","reported_name":"SAUNDERS BRENT L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Stock Options (right to buy)","published_at":"2021-05-10T21:21:00.000Z","date":"2021-05-06","kind":"grant","acquired":true,"shares":1860000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F2","text":"Represents a grant of stock options under The Beauty Health Company 2021 Incentive Award Plan.  Subject to accelerated vesting in certain circumstances, twenty-five percent (25%) of the stock options are scheduled to vest on each of the first four anniversaries of May 6, 2021, as long as the reporting person remains in the service of The Beauty Health Company through the applicable vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Represents a grant of stock options under The Beauty Health Company 2021 Incentive Award Plan.  Subject to accelerated vesting in certain circumstances, twenty-five percent (25%) of the stock options are scheduled to vest on each of the first four anniversaries of May 6, 2021, as long as the reporting person remains in the service of The Beauty Health Company through the applicable vesting date."}],"balance_after":1860000,"derivative":{"exercise_price":12.85,"expiration_date":"2031-05-06","underlying":"Common Stock","underlying_shares":1860000},"source":{"system":"sec-edgar","filing":"0000899243-21-018999","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1818093/000089924321018999/doc4.xml","form_type":"4"}},{"id":2721866,"issuer":{"id":6863,"kind":"organization","name":"SkinHealth Systems Inc.","symbol":"SKIN"},"owners":[{"id":11572,"kind":"person","name":"SAUNDERS BRENT L","position":1,"cik":"0001268854","reported_name":"SAUNDERS BRENT L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Class B Common Stock","published_at":"2021-05-10T21:21:00.000Z","date":"2021-05-04","kind":"exercise","acquired":true,"shares":11500000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of Class B Common Stock converted into shares of Class A Common Stock on a one-for one basis upon the issuer's consummation of its initial business combination.  The securities reported are held of record by BLS Investor Group, LLC.  The reporting person is the managing member of BLS Investor Group, LLC. As such, the reporting person may be deemed to have beneficial ownership of the securities beneficially owned by BLS Investor Group, LLC.  The reporting person disclaims any beneficial ownership of the reported shares other than to the extent of any pecuniary interest he may have therein, directly or indirectly."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The shares of Class B Common Stock converted into shares of Class A Common Stock on a one-for one basis upon the issuer's consummation of its initial business combination.  The securities reported are held of record by BLS Investor Group, LLC.  The reporting person is the managing member of BLS Investor Group, LLC. As such, the reporting person may be deemed to have beneficial ownership of the securities beneficially owned by BLS Investor Group, LLC.  The reporting person disclaims any beneficial ownership of the reported shares other than to the extent of any pecuniary interest he may have therein, directly or indirectly."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares of Class B Common Stock converted into shares of Class A Common Stock on a one-for one basis upon the issuer's consummation of its initial business combination.  The securities reported are held of record by BLS Investor Group, LLC.  The reporting person is the managing member of BLS Investor Group, LLC. As such, the reporting person may be deemed to have beneficial ownership of the securities beneficially owned by BLS Investor Group, LLC.  The reporting person disclaims any beneficial ownership of the reported shares other than to the extent of any pecuniary interest he may have therein, directly or indirectly."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Class A Common Stock","underlying_shares":11500000},"source":{"system":"sec-edgar","filing":"0000899243-21-018999","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818093/000089924321018999/doc4.xml","form_type":"4"}},{"id":2721865,"issuer":{"id":6863,"kind":"organization","name":"SkinHealth Systems Inc.","symbol":"SKIN"},"owners":[{"id":11572,"kind":"person","name":"SAUNDERS BRENT L","position":1,"cik":"0001268854","reported_name":"SAUNDERS BRENT L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Class A Common Stock","published_at":"2021-05-10T21:21:00.000Z","date":"2021-05-04","kind":"exercise","acquired":true,"shares":11500000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares of Class B Common Stock converted into shares of Class A Common Stock on a one-for one basis upon the issuer's consummation of its initial business combination.  The securities reported are held of record by BLS Investor Group, LLC.  The reporting person is the managing member of BLS Investor Group, LLC. As such, the reporting person may be deemed to have beneficial ownership of the securities beneficially owned by BLS Investor Group, LLC.  The reporting person disclaims any beneficial ownership of the reported shares other than to the extent of any pecuniary interest he may have therein, directly or indirectly."}],"balance_after":11500000,"source":{"system":"sec-edgar","filing":"0000899243-21-018999","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818093/000089924321018999/doc4.xml","form_type":"4"}},{"id":96884,"issuer":{"id":2802,"kind":"organization","name":"CISCO SYSTEMS, INC.","symbol":"CSCO"},"owners":[{"id":11572,"kind":"person","name":"SAUNDERS BRENT L","position":1,"cik":"0001268854","reported_name":"SAUNDERS BRENT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-12-15T00:02:52.000Z","date":"2020-12-10","kind":"grant","acquired":true,"shares":5189,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a fully vested deferred restricted stock unit award covering shares which will settle in shares on, or as soon as practicable after, the reporting person's \"separation from service\" to Cisco within the meaning of Section 409A of the Internal Revenue Code."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 1,564 dividend equivalents accrued on vested deferred restricted stock units.  Each dividend equivalent is the economic equivalent of one share of Cisco common stock."}],"balance_after":27543,"source":{"system":"sec-edgar","filing":"0001209191-20-063336","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/858877/000120919120063336/doc4.xml","form_type":"4"}},{"id":3099867,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":11572,"kind":"person","name":"SAUNDERS BRENT L","position":1,"cik":"0001268854","reported_name":"SAUNDERS BRENT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-25T20:41:20.000Z","date":"2020-06-23","kind":"grant","acquired":true,"shares":101223,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option vest and become exercisable in three annual installments after June 23, 2020, subject to the Reporting Person's continued service to the Issuer through each such vesting date."}],"balance_after":101223,"derivative":{"exercise_price":32.62,"expiration_date":"2030-06-22","underlying":"Common Stock","underlying_shares":101223},"source":{"system":"sec-edgar","filing":"0000899243-20-017666","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924320017666/doc4.xml","form_type":"4"}},{"id":3154223,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":11572,"kind":"person","name":"SAUNDERS BRENT L","position":1,"cik":"0001268854","reported_name":"SAUNDERS BRENT L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman, President and CEO"}}],"security":"Performance Stock Units","published_at":"2020-05-12T01:36:58.000Z","date":"2020-05-08","kind":"disposition_to_issuer","acquired":false,"shares":83936,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Reflects the disposition of performance stock units relating to Allergan Shares (\"Allergan PSUs\") as contemplated by the Transaction Agreement.  In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, was substituted by AbbVie with an AbbVie restricted stock unit award relating to shares of AbbVie common stock, that vests based on the holder's continued service following the effective time of the Scheme, with the number of shares of AbbVie common stock subject to such award determined in accordance with the formulas set forth in the Transaction Agreement (which, for any Allergan performance stock unit awards that were subject to performance-based vesting conditions on June 25, 2019, was calculated based on deemed satisfaction of performance at 130% of target)."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Reflects the disposition of performance stock units relating to Allergan Shares (\"Allergan PSUs\") as contemplated by the Transaction Agreement.  In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, was substituted by AbbVie with an AbbVie restricted stock unit award relating to shares of AbbVie common stock, that vests based on the holder's continued service following the effective time of the Scheme, with the number of shares of AbbVie common stock subject to such award determined in accordance with the formulas set forth in the Transaction Agreement (which, for any Allergan performance stock unit awards that were subject to performance-based vesting conditions on June 25, 2019, was calculated based on deemed satisfaction of performance at 130% of target)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Reflects the disposition of performance stock units relating to Allergan Shares (\"Allergan PSUs\") as contemplated by the Transaction Agreement.  In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, was substituted by AbbVie with an AbbVie restricted stock unit award relating to shares of AbbVie common stock, that vests based on the holder's continued service following the effective time of the Scheme, with the number of shares of AbbVie common stock subject to such award determined in accordance with the formulas set forth in the Transaction Agreement (which, for any Allergan performance stock unit awards that were subject to performance-based vesting conditions on June 25, 2019, was calculated based on deemed satisfaction of performance at 130% of target)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Reflects the disposition of performance stock units relating to Allergan Shares (\"Allergan PSUs\") as contemplated by the Transaction Agreement.  In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, was substituted by AbbVie with an AbbVie restricted stock unit award relating to shares of AbbVie common stock, that vests based on the holder's continued service following the effective time of the Scheme, with the number of shares of AbbVie common stock subject to such award determined in accordance with the formulas set forth in the Transaction Agreement (which, for any Allergan performance stock unit awards that were subject to performance-based vesting conditions on June 25, 2019, was calculated based on deemed satisfaction of performance at 130% of target)."}],"balance_after":0,"derivative":{"underlying":"Ordinary Shares","underlying_shares":83936},"source":{"system":"sec-edgar","filing":"0000899243-20-012730","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1268854/000089924320012730/doc4.xml","form_type":"4"}},{"id":3154222,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":11572,"kind":"person","name":"SAUNDERS BRENT L","position":1,"cik":"0001268854","reported_name":"SAUNDERS BRENT L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman, President and CEO"}}],"security":"Stock Options","published_at":"2020-05-12T01:36:58.000Z","date":"2020-05-08","kind":"disposition_to_issuer","acquired":false,"shares":1,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Reflects the disposition of Allergan Options as contemplated by the Transaction Agreement.  In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Option was substituted by AbbVie with a corresponding AbbVie stock option relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such stock option and the exercise price per share applicable to such stock option determined in accordance with the formulas set forth in the Transaction Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"All of the stock options to purchase Allergan Shares (\"Allergan Options\") were vested as of May 8, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Reflects the disposition of Allergan Options as contemplated by the Transaction Agreement.  In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Option was substituted by AbbVie with a corresponding AbbVie stock option relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such stock option and the exercise price per share applicable to such stock option determined in accordance with the formulas set forth in the Transaction Agreement."}],"balance_after":0,"derivative":{"exercise_price":196.16,"expiration_date":"2024-05-12","underlying":"Ordinary Shares","underlying_shares":1},"source":{"system":"sec-edgar","filing":"0000899243-20-012730","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1268854/000089924320012730/doc4.xml","form_type":"4"}},{"id":3154221,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":11572,"kind":"person","name":"SAUNDERS BRENT L","position":1,"cik":"0001268854","reported_name":"SAUNDERS BRENT L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman, President and CEO"}}],"security":"Stock Options","published_at":"2020-05-12T01:36:58.000Z","date":"2020-05-08","kind":"disposition_to_issuer","acquired":false,"shares":62547,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Reflects the disposition of Allergan Options as contemplated by the Transaction Agreement.  In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Option was substituted by AbbVie with a corresponding AbbVie stock option relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such stock option and the exercise price per share applicable to such stock option determined in accordance with the formulas set forth in the Transaction Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"All of the stock options to purchase Allergan Shares (\"Allergan Options\") were vested as of May 8, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Reflects the disposition of Allergan Options as contemplated by the Transaction Agreement.  In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Option was substituted by AbbVie with a corresponding AbbVie stock option relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such stock option and the exercise price per share applicable to such stock option determined in accordance with the formulas set forth in the Transaction Agreement."}],"balance_after":0,"derivative":{"exercise_price":196.16,"expiration_date":"2024-05-12","underlying":"Ordinary Shares","underlying_shares":62547},"source":{"system":"sec-edgar","filing":"0000899243-20-012730","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1268854/000089924320012730/doc4.xml","form_type":"4"}},{"id":3154220,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":11572,"kind":"person","name":"SAUNDERS BRENT L","position":1,"cik":"0001268854","reported_name":"SAUNDERS BRENT L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman, President and CEO"}}],"security":"Stock Options","published_at":"2020-05-12T01:36:58.000Z","date":"2020-05-08","kind":"disposition_to_issuer","acquired":false,"shares":219667,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Reflects the disposition of Allergan Options as contemplated by the Transaction Agreement.  In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Option was substituted by AbbVie with a corresponding AbbVie stock option relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such stock option and the exercise price per share applicable to such stock option determined in accordance with the formulas set forth in the Transaction Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"All of the stock options to purchase Allergan Shares (\"Allergan Options\") were vested as of May 8, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Reflects the disposition of Allergan Options as contemplated by the Transaction Agreement.  In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Option was substituted by AbbVie with a corresponding AbbVie stock option relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such stock option and the exercise price per share applicable to such stock option determined in accordance with the formulas set forth in the Transaction Agreement."}],"balance_after":0,"derivative":{"exercise_price":91.13,"expiration_date":"2023-09-30","underlying":"Ordinary Shares","underlying_shares":219667},"source":{"system":"sec-edgar","filing":"0000899243-20-012730","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1268854/000089924320012730/doc4.xml","form_type":"4"}},{"id":3154219,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":11572,"kind":"person","name":"SAUNDERS BRENT L","position":1,"cik":"0001268854","reported_name":"SAUNDERS BRENT L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman, President and CEO"}}],"security":"Stock Options","published_at":"2020-05-12T01:36:58.000Z","date":"2020-05-08","kind":"disposition_to_issuer","acquired":false,"shares":2790,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Reflects the disposition of Allergan Options as contemplated by the Transaction Agreement.  In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Option was substituted by AbbVie with a corresponding AbbVie stock option relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such stock option and the exercise price per share applicable to such stock option determined in accordance with the formulas set forth in the Transaction Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"All of the stock options to purchase Allergan Shares (\"Allergan Options\") were vested as of May 8, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Reflects the disposition of Allergan Options as contemplated by the Transaction Agreement.  In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Option was substituted by AbbVie with a corresponding AbbVie stock option relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such stock option and the exercise price per share applicable to such stock option determined in accordance with the formulas set forth in the Transaction Agreement."}],"balance_after":0,"derivative":{"exercise_price":90.22,"expiration_date":"2023-08-14","underlying":"Ordinary Shares","underlying_shares":2790},"source":{"system":"sec-edgar","filing":"0000899243-20-012730","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1268854/000089924320012730/doc4.xml","form_type":"4"}},{"id":3154218,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":11572,"kind":"person","name":"SAUNDERS BRENT L","position":1,"cik":"0001268854","reported_name":"SAUNDERS BRENT L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman, President and CEO"}}],"security":"Stock Options","published_at":"2020-05-12T01:36:58.000Z","date":"2020-05-08","kind":"disposition_to_issuer","acquired":false,"shares":3691,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Reflects the disposition of Allergan Options as contemplated by the Transaction Agreement.  In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Option was substituted by AbbVie with a corresponding AbbVie stock option relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such stock option and the exercise price per share applicable to such stock option determined in accordance with the formulas set forth in the Transaction Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"All of the stock options to purchase Allergan Shares (\"Allergan Options\") were vested as of May 8, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Reflects the disposition of Allergan Options as contemplated by the Transaction Agreement.  In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Option was substituted by AbbVie with a corresponding AbbVie stock option relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such stock option and the exercise price per share applicable to such stock option determined in accordance with the formulas set forth in the Transaction Agreement."}],"balance_after":0,"derivative":{"exercise_price":73.14,"expiration_date":"2022-08-22","underlying":"Ordinary Shares","underlying_shares":3691},"source":{"system":"sec-edgar","filing":"0000899243-20-012730","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1268854/000089924320012730/doc4.xml","form_type":"4"}},{"id":3154217,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":11572,"kind":"person","name":"SAUNDERS BRENT L","position":1,"cik":"0001268854","reported_name":"SAUNDERS BRENT L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman, President and CEO"}}],"security":"Stock Options","published_at":"2020-05-12T01:36:58.000Z","date":"2020-05-08","kind":"disposition_to_issuer","acquired":false,"shares":9446,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Reflects the disposition of Allergan Options as contemplated by the Transaction Agreement.  In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Option was substituted by AbbVie with a corresponding AbbVie stock option relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such stock option and the exercise price per share applicable to such stock option determined in accordance with the formulas set forth in the Transaction Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"All of the stock options to purchase Allergan Shares (\"Allergan Options\") were vested as of May 8, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Reflects the disposition of Allergan Options as contemplated by the Transaction Agreement.  In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Option was substituted by AbbVie with a corresponding AbbVie stock option relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such stock option and the exercise price per share applicable to such stock option determined in accordance with the formulas set forth in the Transaction Agreement."}],"balance_after":0,"derivative":{"exercise_price":70.79,"expiration_date":"2021-08-22","underlying":"Ordinary Shares","underlying_shares":9446},"source":{"system":"sec-edgar","filing":"0000899243-20-012730","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1268854/000089924320012730/doc4.xml","form_type":"4"}},{"id":3154216,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":11572,"kind":"person","name":"SAUNDERS BRENT L","position":1,"cik":"0001268854","reported_name":"SAUNDERS BRENT L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman, President and CEO"}}],"security":"Stock Options","published_at":"2020-05-12T01:36:58.000Z","date":"2020-05-08","kind":"disposition_to_issuer","acquired":false,"shares":1018,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Reflects the disposition of Allergan Options as contemplated by the Transaction Agreement.  In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Option was substituted by AbbVie with a corresponding AbbVie stock option relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such stock option and the exercise price per share applicable to such stock option determined in accordance with the formulas set forth in the Transaction Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"All of the stock options to purchase Allergan Shares (\"Allergan Options\") were vested as of May 8, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Reflects the disposition of Allergan Options as contemplated by the Transaction Agreement.  In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Option was substituted by AbbVie with a corresponding AbbVie stock option relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such stock option and the exercise price per share applicable to such stock option determined in accordance with the formulas set forth in the Transaction Agreement."}],"balance_after":0,"derivative":{"exercise_price":196.16,"expiration_date":"2024-05-12","underlying":"Ordinary Shares","underlying_shares":1018},"source":{"system":"sec-edgar","filing":"0000899243-20-012730","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1268854/000089924320012730/doc4.xml","form_type":"4"}},{"id":3154215,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":11572,"kind":"person","name":"SAUNDERS BRENT L","position":1,"cik":"0001268854","reported_name":"SAUNDERS BRENT L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman, President and CEO"}}],"security":"Stock Options","published_at":"2020-05-12T01:36:58.000Z","date":"2020-05-08","kind":"disposition_to_issuer","acquired":false,"shares":3291,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Reflects the disposition of Allergan Options as contemplated by the Transaction Agreement.  In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Option was substituted by AbbVie with a corresponding AbbVie stock option relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such stock option and the exercise price per share applicable to such stock option determined in accordance with the formulas set forth in the Transaction Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"All of the stock options to purchase Allergan Shares (\"Allergan Options\") were vested as of May 8, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Reflects the disposition of Allergan Options as contemplated by the Transaction Agreement.  In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Option was substituted by AbbVie with a corresponding AbbVie stock option relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such stock option and the exercise price per share applicable to such stock option determined in accordance with the formulas set forth in the Transaction Agreement."}],"balance_after":0,"derivative":{"exercise_price":91.13,"expiration_date":"2023-09-30","underlying":"Ordinary Shares","underlying_shares":3291},"source":{"system":"sec-edgar","filing":"0000899243-20-012730","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1268854/000089924320012730/doc4.xml","form_type":"4"}},{"id":3154214,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":11572,"kind":"person","name":"SAUNDERS BRENT L","position":1,"cik":"0001268854","reported_name":"SAUNDERS BRENT L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman, President and CEO"}}],"security":"Stock Options","published_at":"2020-05-12T01:36:58.000Z","date":"2020-05-08","kind":"disposition_to_issuer","acquired":false,"shares":104651,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Reflects the disposition of Allergan Options as contemplated by the Transaction Agreement.  In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Option was substituted by AbbVie with a corresponding AbbVie stock option relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such stock option and the exercise price per share applicable to such stock option determined in accordance with the formulas set forth in the Transaction Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"All of the stock options to purchase Allergan Shares (\"Allergan Options\") were vested as of May 8, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Reflects the disposition of Allergan Options as contemplated by the Transaction Agreement.  In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Option was substituted by AbbVie with a corresponding AbbVie stock option relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such stock option and the exercise price per share applicable to such stock option determined in accordance with the formulas set forth in the Transaction Agreement."}],"balance_after":0,"derivative":{"exercise_price":224,"expiration_date":"2023-05-08","underlying":"Ordinary Shares","underlying_shares":104651},"source":{"system":"sec-edgar","filing":"0000899243-20-012730","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1268854/000089924320012730/doc4.xml","form_type":"4"}},{"id":3154213,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":11572,"kind":"person","name":"SAUNDERS BRENT L","position":1,"cik":"0001268854","reported_name":"SAUNDERS BRENT L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman, President and CEO"}}],"security":"Restricted Stock Units","published_at":"2020-05-12T01:36:58.000Z","date":"2020-05-08","kind":"disposition_to_issuer","acquired":false,"shares":79805,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Reflects the disposition of restricted stock units relating to Allergan Shares (\"Allergan RSUs\") as contemplated by the Transaction Agreement.  In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan RSU was substituted by AbbVie with a corresponding AbbVie restricted stock unit award relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such award determined in accordance with the formula set forth in the Transaction Agreement."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-20-012730","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1268854/000089924320012730/doc4.xml","form_type":"4"}},{"id":3154212,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":11572,"kind":"person","name":"SAUNDERS BRENT L","position":1,"cik":"0001268854","reported_name":"SAUNDERS BRENT L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman, President and CEO"}}],"security":"Ordinary Shares, par value $0.0001","published_at":"2020-05-12T01:36:58.000Z","date":"2020-05-08","kind":"disposition_to_issuer","acquired":false,"shares":149384.28,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Reflects the disposition of ordinary shares (\"Allergan Shares\") of Allergan plc (\"Allergan\") as contemplated by the Transaction Agreement dated as of June 25, 2019 among AbbVie Inc. (\"AbbVie\"), Venice Subsidiary, LLC (\"Acquirer Sub\") and Allergan (the \"Transaction Agreement\"), pursuant to which Acquirer Sub acquired Allergan pursuant to a scheme of arrangement under Chapter 1 of Part 9 of the Irish Companies Act of 2014 and the capital reduction under Sections 84 and 85 of the Act (the \"Scheme\").  In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Share was converted into $120.30 in cash and 0.8660 of a newly issued share of AbbVie common stock, par value $0.01 per share."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-20-012730","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1268854/000089924320012730/doc4.xml","form_type":"4"}},{"id":3227182,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":11572,"kind":"person","name":"SAUNDERS BRENT L","position":1,"cik":"0001268854","reported_name":"SAUNDERS BRENT L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman, President and CEO"}}],"security":"Ordinary Shares, par value $0.0001","published_at":"2020-03-04T19:16:54.000Z","date":"2020-03-02","kind":"grant","acquired":true,"shares":68613,"price":193.84,"value":13299943.92,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes restricted stock units issued pursuant to the Amended and Restated 2013 Incentive Award Plan of Allergan plc."}],"balance_after":229189.29,"source":{"system":"sec-edgar","filing":"0001179110-20-003037","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1268854/000117911020003037/edgar.xml","form_type":"4"}},{"id":3326904,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":11572,"kind":"person","name":"SAUNDERS BRENT L","position":1,"cik":"0001268854","reported_name":"SAUNDERS BRENT L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman, President and CEO"}}],"security":"Ordinary Shares, par value $0.0001","published_at":"2020-01-02T22:49:53.000Z","date":"2019-12-31","kind":"tax_withholding","acquired":false,"shares":7333,"price":191.17,"value":1401849.61,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes restricted stock units issued pursuant to the 2013 Incentive Award Plan of Allergan plc."}],"balance_after":160576.29,"source":{"system":"sec-edgar","filing":"0001179110-20-000039","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1268854/000117911020000039/edgar.xml","form_type":"4"}},{"id":109853,"issuer":{"id":2802,"kind":"organization","name":"CISCO SYSTEMS, INC.","symbol":"CSCO"},"owners":[{"id":11572,"kind":"person","name":"SAUNDERS BRENT L","position":1,"cik":"0001268854","reported_name":"SAUNDERS BRENT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-12-13T02:29:02.000Z","date":"2019-12-10","kind":"grant","acquired":true,"shares":5215,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a fully vested deferred restricted stock unit award covering shares which will settle in shares on, or as soon as practicable after, the reporting person's \"separation from service\" to Cisco within the meaning of Section 409A of the Internal Revenue Code."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 863 dividend equivalents accrued on vested deferred restricted stock units. Each dividend equivalent is the economic equivalent of one share of Cisco common stock."}],"balance_after":21653,"source":{"system":"sec-edgar","filing":"0001567619-19-023022","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/858877/000156761919023022/doc1.xml","form_type":"4"}},{"id":3561198,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":11572,"kind":"person","name":"SAUNDERS BRENT L","position":1,"cik":"0001268854","reported_name":"SAUNDERS BRENT L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman, President and CEO"}}],"security":"Ordinary Shares, par value $0.0001","published_at":"2019-04-05T19:15:02.000Z","date":"2019-04-05","kind":"tax_withholding","acquired":false,"shares":2757,"price":145.71,"value":401722.47,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes restricted stock units issued pursuant to the 2013 Incentive Award Plan of Allergan plc."}],"balance_after":167909.29,"source":{"system":"sec-edgar","filing":"0001179110-19-004798","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1268854/000117911019004798/edgar.xml","form_type":"4"}},{"id":3605983,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":11572,"kind":"person","name":"SAUNDERS BRENT L","position":1,"cik":"0001268854","reported_name":"SAUNDERS BRENT L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman, President and CEO"}}],"security":"Ordinary Shares, par value $0.0001","published_at":"2019-03-07T20:19:02.000Z","date":"2019-03-07","kind":"purchase","acquired":true,"shares":600,"price":144.37,"value":86622.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $144.15 to $144.55, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes restricted stock units issued pursuant to the 2013 Incentive Award Plan of Allergan plc."}],"balance_after":170666.29,"source":{"system":"sec-edgar","filing":"0001179110-19-003505","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1268854/000117911019003505/edgar.xml","form_type":"4"}},{"id":3605982,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":11572,"kind":"person","name":"SAUNDERS BRENT L","position":1,"cik":"0001268854","reported_name":"SAUNDERS BRENT L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman, President and CEO"}}],"security":"Ordinary Shares, par value $0.0001","published_at":"2019-03-07T20:19:02.000Z","date":"2019-03-07","kind":"purchase","acquired":true,"shares":860,"price":143.7,"value":123582.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $143.13 to $143.91, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes restricted stock units issued pursuant to the 2013 Incentive Award Plan of Allergan plc."}],"balance_after":170066.29,"source":{"system":"sec-edgar","filing":"0001179110-19-003505","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1268854/000117911019003505/edgar.xml","form_type":"4"}},{"id":3605981,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":11572,"kind":"person","name":"SAUNDERS BRENT L","position":1,"cik":"0001268854","reported_name":"SAUNDERS BRENT L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman, President and CEO"}}],"security":"Ordinary Shares, par value $0.0001","published_at":"2019-03-07T20:19:02.000Z","date":"2019-03-07","kind":"purchase","acquired":true,"shares":300,"price":142.18,"value":42654.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $142.09 to $142.35, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes restricted stock units issued pursuant to the 2013 Incentive Award Plan of Allergan plc."}],"balance_after":169206.29,"source":{"system":"sec-edgar","filing":"0001179110-19-003505","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1268854/000117911019003505/edgar.xml","form_type":"4"}},{"id":3708183,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":11572,"kind":"person","name":"SAUNDERS BRENT L","position":1,"cik":"0001268854","reported_name":"SAUNDERS BRENT L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman, President and CEO"}}],"security":"Ordinary Shares, par value $0.0001","published_at":"2019-01-03T20:57:59.000Z","date":"2018-12-31","kind":"tax_withholding","acquired":false,"shares":9269,"price":133.66,"value":1238894.54,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc."}],"balance_after":168906.29,"source":{"system":"sec-edgar","filing":"0001179110-19-000199","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1268854/000117911019000199/edgar.xml","form_type":"4"}},{"id":121823,"issuer":{"id":2802,"kind":"organization","name":"CISCO SYSTEMS, INC.","symbol":"CSCO"},"owners":[{"id":11572,"kind":"person","name":"SAUNDERS BRENT L","position":1,"cik":"0001268854","reported_name":"SAUNDERS BRENT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-12-14T22:05:01.000Z","date":"2018-12-12","kind":"grant","acquired":true,"shares":4744,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a fully vested deferred restricted stock unit award covering shares which will settle in shares on, or as soon as practicable after, the reporting person's \"separation from service\" to Cisco within the meaning of Section 409A of the Internal Revenue Code."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 439 dividend equivalents accrued on vested deferred restricted stock units. Each dividend equivalent is the economic equivalent of one share of Cisco common stock."}],"balance_after":16014,"source":{"system":"sec-edgar","filing":"0001567619-18-008032","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/858877/000156761918008032/doc1.xml","form_type":"4"}},{"id":3968345,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":11572,"kind":"person","name":"SAUNDERS BRENT L","position":1,"cik":"0001268854","reported_name":"SAUNDERS BRENT L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman, President and CEO"}}],"security":"Ordinary Shares, par value $0.0001","published_at":"2018-04-05T22:58:56.000Z","date":"2018-04-03","kind":"tax_withholding","acquired":false,"shares":2756,"price":164.74,"value":454023.44,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc."}],"balance_after":178175.29,"source":{"system":"sec-edgar","filing":"0000903423-18-000201","document":"saundersf4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1268854/000090342318000201/saundersf4.xml","form_type":"4"}},{"id":4005114,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":11572,"kind":"person","name":"SAUNDERS BRENT L","position":1,"cik":"0001268854","reported_name":"SAUNDERS BRENT L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman, President and CEO"}}],"security":"Ordinary Shares, par value $0.0001","published_at":"2018-03-08T15:25:05.000Z","date":"2018-03-08","kind":"purchase","acquired":true,"shares":3300,"price":152.53,"value":503349.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc."}],"balance_after":180931.29,"source":{"system":"sec-edgar","filing":"0001179110-18-003827","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1268854/000117911018003827/edgar.xml","form_type":"4"}},{"id":4116988,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":11572,"kind":"person","name":"SAUNDERS BRENT L","position":1,"cik":"0001268854","reported_name":"SAUNDERS BRENT L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman, President and CEO"}}],"security":"Ordinary Shares, par value $0.0001","published_at":"2018-01-02T21:38:19.000Z","date":"2017-12-29","kind":"tax_withholding","acquired":false,"shares":8746,"price":163.58,"value":1430670.68,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc."}],"balance_after":177631.29,"source":{"system":"sec-edgar","filing":"0001179110-18-000111","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1268854/000117911018000111/edgar.xml","form_type":"4"}},{"id":134457,"issuer":{"id":2802,"kind":"organization","name":"CISCO SYSTEMS, INC.","symbol":"CSCO"},"owners":[{"id":11572,"kind":"person","name":"SAUNDERS BRENT L","position":1,"cik":"0001268854","reported_name":"SAUNDERS BRENT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-12-13T22:39:26.000Z","date":"2017-12-11","kind":"grant","acquired":true,"shares":5663,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a fully vested deferred restricted stock unit award covering shares which will settle in shares on, or as soon as practicable after, the reporting person's \"separation from service\" to Cisco within the meaning of Section 409A of the Internal Revenue Code."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 125 dividend equivalents accrued on vested deferred restricted stock units. Each dividend equivalent is the economic equivalent of one share of Cisco common stock."}],"balance_after":10956,"source":{"system":"sec-edgar","filing":"0001140361-17-046098","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/858877/000114036117046098/doc1.xml","form_type":"4"}},{"id":4140263,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":11572,"kind":"person","name":"SAUNDERS BRENT L","position":1,"cik":"0001268854","reported_name":"SAUNDERS BRENT L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman, President and CEO"}}],"security":"Ordinary Shares, par value $0.0001","published_at":"2017-12-06T17:31:03.000Z","date":"2017-12-06","kind":"purchase","acquired":true,"shares":200,"price":165.35,"value":33070.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc."}],"balance_after":186377.29,"source":{"system":"sec-edgar","filing":"0001179110-17-014997","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1268854/000117911017014997/edgar.xml","form_type":"4"}},{"id":4140262,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":11572,"kind":"person","name":"SAUNDERS BRENT L","position":1,"cik":"0001268854","reported_name":"SAUNDERS BRENT L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman, President and CEO"}}],"security":"Ordinary Shares, par value $0.0001","published_at":"2017-12-06T17:31:03.000Z","date":"2017-12-06","kind":"purchase","acquired":true,"shares":4400,"price":164.71,"value":724724.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $164.34 to $165.33, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc."}],"balance_after":186177.29,"source":{"system":"sec-edgar","filing":"0001179110-17-014997","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1268854/000117911017014997/edgar.xml","form_type":"4"}},{"id":4178422,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":11572,"kind":"person","name":"SAUNDERS BRENT L","position":1,"cik":"0001268854","reported_name":"SAUNDERS BRENT L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman, President and CEO"}}],"security":"Performance Based Restricted Share Unit","published_at":"2017-10-31T01:24:40.000Z","date":"2017-10-26","kind":"exercise","acquired":false,"shares":50599,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Performance Based Restricted Share Unit or PSU represented a contingent right to receive a number of Ordinary Shares equal to the product of the applicable performance multiple and the target number of shares underlying the PSU, as set forth in the award agreement between the Issuer and the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each Performance Based Restricted Share Unit or PSU represented a contingent right to receive a number of Ordinary Shares equal to the product of the applicable performance multiple and the target number of shares underlying the PSU, as set forth in the award agreement between the Issuer and the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each Performance Based Restricted Share Unit or PSU represented a contingent right to receive a number of Ordinary Shares equal to the product of the applicable performance multiple and the target number of shares underlying the PSU, as set forth in the award agreement between the Issuer and the Reporting Person."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each Performance Based Restricted Share Unit or PSU represented a contingent right to receive a number of Ordinary Shares equal to the product of the applicable performance multiple and the target number of shares underlying the PSU, as set forth in the award agreement between the Issuer and the Reporting Person."}],"balance_after":0,"derivative":{"underlying":"Ordinary Shares","underlying_shares":50599},"source":{"system":"sec-edgar","filing":"0001179110-17-013555","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1268854/000117911017013555/edgar.xml","form_type":"4"}},{"id":4178421,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":11572,"kind":"person","name":"SAUNDERS BRENT L","position":1,"cik":"0001268854","reported_name":"SAUNDERS BRENT L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman, President and CEO"}}],"security":"Ordinary Shares, par value $0.0001","published_at":"2017-10-31T01:24:40.000Z","date":"2017-10-26","kind":"exercise","acquired":true,"shares":50599,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported securities are restricted share units, each of which represents a right to receive one ordinary share of Allergan plc. The restricted share units will vest in equal installments on each of December 31, 2017, December 31, 2018 and December 31, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each Performance Based Restricted Share Unit or PSU represented a contingent right to receive a number of Ordinary Shares equal to the product of the applicable performance multiple and the target number of shares underlying the PSU, as set forth in the award agreement between the Issuer and the Reporting Person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc."}],"balance_after":181777.29,"source":{"system":"sec-edgar","filing":"0001179110-17-013555","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1268854/000117911017013555/edgar.xml","form_type":"4"}},{"id":4207022,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":11572,"kind":"person","name":"SAUNDERS BRENT L","position":1,"cik":"0001268854","reported_name":"SAUNDERS BRENT L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman, President and CEO"}}],"security":"Ordinary Shares, par value $0.001","published_at":"2017-09-19T00:49:19.000Z","date":"2017-06-16","kind":"purchase","acquired":true,"shares":43.768,"price":235.96,"value":10327.49728,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 43.7680 shares acquired on June 16, 2017 pursuant to a broker-assisted dividend reinvestment plan."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc."}],"balance_after":131178.29,"source":{"system":"sec-edgar","filing":"0001179110-17-012396","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1268854/000117911017012396/edgar.xml","form_type":"4"}},{"id":4207021,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":11572,"kind":"person","name":"SAUNDERS BRENT L","position":1,"cik":"0001268854","reported_name":"SAUNDERS BRENT L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman, President and CEO"}}],"security":"Ordinary Shares, par value $0.001","published_at":"2017-09-19T00:49:19.000Z","date":"2017-03-29","kind":"purchase","acquired":true,"shares":42.52,"price":242.21,"value":10298.7692,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 42.52 shares acquired on March 29, 2017 pursuant to a broker-assisted dividend reinvestment plan."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc."}],"balance_after":131134.52,"source":{"system":"sec-edgar","filing":"0001179110-17-012396","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1268854/000117911017012396/edgar.xml","form_type":"4"}},{"id":4318036,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":11572,"kind":"person","name":"SAUNDERS BRENT L","position":1,"cik":"0001268854","reported_name":"SAUNDERS BRENT L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman, President and CEO"}}],"security":"Ordinary Shares, par value $0.0001","published_at":"2017-05-16T22:09:45.000Z","date":"2017-05-15","kind":"tax_withholding","acquired":false,"shares":3450,"price":228.22,"value":787359.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc."}],"balance_after":131092,"source":{"system":"sec-edgar","filing":"0001179110-17-007337","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1268854/000117911017007337/edgar.xml","form_type":"4"}},{"id":4360439,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":11572,"kind":"person","name":"SAUNDERS BRENT L","position":1,"cik":"0001268854","reported_name":"SAUNDERS BRENT L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman, President and CEO"}}],"security":"Ordinary Shares, par value $0.0001","published_at":"2017-04-04T20:24:07.000Z","date":"2017-04-03","kind":"grant","acquired":true,"shares":27978,"price":237.68,"value":6649811.04,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported securities are restricted share units, each of which represents a right to receive one ordinary share of Allergan plc. The restricted share units will vest twenty percent (20%) on April 3, 2018, twenty percent (20%) on April 3, 2019, twenty percent (20%) on April 3, 2020, twenty percent (20%) on April 3, 2021 and twenty percent (20%) on April 3, 2022."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc."}],"balance_after":134542,"source":{"system":"sec-edgar","filing":"0001179110-17-005550","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1268854/000117911017005550/edgar.xml","form_type":"4"}},{"id":142170,"issuer":{"id":2802,"kind":"organization","name":"CISCO SYSTEMS, INC.","symbol":"CSCO"},"owners":[{"id":11572,"kind":"person","name":"SAUNDERS BRENT L","position":1,"cik":"0001268854","reported_name":"SAUNDERS BRENT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-03-14T22:38:33.000Z","date":"2017-03-13","kind":"grant","acquired":true,"shares":4728,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a fully vested deferred restricted stock unit award covering shares which will settle in shares on, or as soon as practicable after, the reporting person's \"separation from service\" to Cisco within the meaning of Section 409A of the Internal Revenue Code."}],"balance_after":5168,"source":{"system":"sec-edgar","filing":"0001140361-17-011969","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/858877/000114036117011969/doc1.xml","form_type":"4"}},{"id":4546924,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":11572,"kind":"person","name":"SAUNDERS BRENT L","position":1,"cik":"0001268854","reported_name":"SAUNDERS BRENT L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Ordinary Shares, par value $0.0001","published_at":"2016-11-21T21:03:11.000Z","date":"2016-11-21","kind":"purchase","acquired":true,"shares":5250,"price":189.1316,"value":992940.9,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $188.43 to $189.81, inclusive. The reporting person undertakes to provide Allergan plc, any security holder of Allergan plc, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price range set forth in footnote (1) of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc."}],"balance_after":106564,"source":{"system":"sec-edgar","filing":"0001179110-16-031890","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1268854/000117911016031890/edgar.xml","form_type":"4"}},{"id":4589970,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":11572,"kind":"person","name":"SAUNDERS BRENT L","position":1,"cik":"0001268854","reported_name":"SAUNDERS BRENT L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Ordinary Shares, par value $0.0001","published_at":"2016-10-03T22:29:34.000Z","date":"2016-10-01","kind":"tax_withholding","acquired":false,"shares":7587,"price":230.31,"value":1747361.97,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc."}],"balance_after":101314,"source":{"system":"sec-edgar","filing":"0001179110-16-030198","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1268854/000117911016030198/edgar.xml","form_type":"4"}},{"id":220184,"issuer":{"id":2807,"kind":"organization","name":"Merck & Co., Inc."},"owners":[{"id":11572,"kind":"person","name":"SAUNDERS BRENT L","position":1,"cik":"0001268854","reported_name":"SAUNDERS BRENT L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President"}}],"security":"Phantom Stock Unit","published_at":"2009-11-04T23:01:08.000Z","date":"2009-11-03","kind":"disposition_to_issuer","acquired":false,"shares":65587.15,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each unit of phantom stock is the economic equivalent of one share of common stock."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"In connection with the Merger, each unit of phantom stock was converted into 0.5767 phantom shares of Merck & Co., Inc. common stock and $10.50 in cash. The cash value of the phantom stock units will be paid to the reporting person in accordance with the reporting person's distribution election under the Issuer's nonqualified deferred compensation plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"In connection with the Merger, each unit of phantom stock was converted into 0.5767 phantom shares of Merck & Co., Inc. common stock and $10.50 in cash. The cash value of the phantom stock units will be paid to the reporting person in accordance with the reporting person's distribution election under the Issuer's nonqualified deferred compensation plan."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"In connection with the Merger, each unit of phantom stock was converted into 0.5767 phantom shares of Merck & Co., Inc. common stock and $10.50 in cash. The cash value of the phantom stock units will be paid to the reporting person in accordance with the reporting person's distribution election under the Issuer's nonqualified deferred compensation plan."}],"balance_after":0,"derivative":{"underlying":"Common Shares","underlying_shares":65587.15},"source":{"system":"sec-edgar","filing":"0001209191-09-051079","document":"c91857_4x1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/310158/000120919109051079/c91857_4x1.xml","form_type":"4"}},{"id":220183,"issuer":{"id":2807,"kind":"organization","name":"Merck & Co., Inc."},"owners":[{"id":11572,"kind":"person","name":"SAUNDERS BRENT L","position":1,"cik":"0001268854","reported_name":"SAUNDERS BRENT L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President"}}],"security":"Option (right to buy)","published_at":"2009-11-04T23:01:08.000Z","date":"2009-11-03","kind":"disposition_to_issuer","acquired":false,"shares":130100,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Merck & Co., Inc. in accordance with the exchange ratio set forth in the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vested and became exercisable (or will vest and become exercisable) on varying dates pursuant to the terms of the plans under which they were granted. Options that had not vested prior to the Merger, vested upon the closing of the Merger or will vest upon the reporting person's termination of employment thereafter."}],"balance_after":0,"derivative":{"exercise_price":22.91,"expiration_date":"2016-04-30","underlying":"Common Shares","underlying_shares":130100},"source":{"system":"sec-edgar","filing":"0001209191-09-051079","document":"c91857_4x1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/310158/000120919109051079/c91857_4x1.xml","form_type":"4"}},{"id":220182,"issuer":{"id":2807,"kind":"organization","name":"Merck & Co., Inc."},"owners":[{"id":11572,"kind":"person","name":"SAUNDERS BRENT L","position":1,"cik":"0001268854","reported_name":"SAUNDERS BRENT L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President"}}],"security":"Option (right to buy)","published_at":"2009-11-04T23:01:08.000Z","date":"2009-11-03","kind":"disposition_to_issuer","acquired":false,"shares":130000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Merck & Co., Inc. in accordance with the exchange ratio set forth in the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vested and became exercisable (or will vest and become exercisable) on varying dates pursuant to the terms of the plans under which they were granted. Options that had not vested prior to the Merger, vested upon the closing of the Merger or will vest upon the reporting person's termination of employment thereafter."}],"balance_after":0,"derivative":{"exercise_price":18.85,"expiration_date":"2015-04-30","underlying":"Common Shares","underlying_shares":130000},"source":{"system":"sec-edgar","filing":"0001209191-09-051079","document":"c91857_4x1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/310158/000120919109051079/c91857_4x1.xml","form_type":"4"}},{"id":220181,"issuer":{"id":2807,"kind":"organization","name":"Merck & Co., Inc."},"owners":[{"id":11572,"kind":"person","name":"SAUNDERS BRENT L","position":1,"cik":"0001268854","reported_name":"SAUNDERS BRENT L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President"}}],"security":"Option (right to buy)","published_at":"2009-11-04T23:01:08.000Z","date":"2009-11-03","kind":"disposition_to_issuer","acquired":false,"shares":130000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Merck & Co., Inc. in accordance with the exchange ratio set forth in the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vested and became exercisable (or will vest and become exercisable) on varying dates pursuant to the terms of the plans under which they were granted. Options that had not vested prior to the Merger, vested upon the closing of the Merger or will vest upon the reporting person's termination of employment thereafter."}],"balance_after":0,"derivative":{"exercise_price":20.7,"expiration_date":"2015-04-24","underlying":"Common Shares","underlying_shares":130000},"source":{"system":"sec-edgar","filing":"0001209191-09-051079","document":"c91857_4x1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/310158/000120919109051079/c91857_4x1.xml","form_type":"4"}},{"id":220180,"issuer":{"id":2807,"kind":"organization","name":"Merck & Co., Inc."},"owners":[{"id":11572,"kind":"person","name":"SAUNDERS BRENT L","position":1,"cik":"0001268854","reported_name":"SAUNDERS BRENT L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President"}}],"security":"Option (right to buy)","published_at":"2009-11-04T23:01:08.000Z","date":"2009-11-03","kind":"disposition_to_issuer","acquired":false,"shares":140000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Merck & Co., Inc. in accordance with the exchange ratio set forth in the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vested and became exercisable (or will vest and become exercisable) on varying dates pursuant to the terms of the plans under which they were granted. Options that had not vested prior to the Merger, vested upon the closing of the Merger or will vest upon the reporting person's termination of employment thereafter."}],"balance_after":0,"derivative":{"exercise_price":31.57,"expiration_date":"2014-04-30","underlying":"Common Shares","underlying_shares":140000},"source":{"system":"sec-edgar","filing":"0001209191-09-051079","document":"c91857_4x1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/310158/000120919109051079/c91857_4x1.xml","form_type":"4"}},{"id":220179,"issuer":{"id":2807,"kind":"organization","name":"Merck & Co., Inc."},"owners":[{"id":11572,"kind":"person","name":"SAUNDERS BRENT L","position":1,"cik":"0001268854","reported_name":"SAUNDERS BRENT L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President"}}],"security":"Option (Right to Buy)","published_at":"2009-11-04T23:01:08.000Z","date":"2009-11-03","kind":"disposition_to_issuer","acquired":false,"shares":100000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Merck & Co., Inc. in accordance with the exchange ratio set forth in the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vested and became exercisable (or will vest and become exercisable) on varying dates pursuant to the terms of the plans under which they were granted. Options that had not vested prior to the Merger, vested upon the closing of the Merger or will vest upon the reporting person's termination of employment thereafter."}],"balance_after":0,"derivative":{"exercise_price":18.2,"expiration_date":"2014-02-22","underlying":"Common Shares","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001209191-09-051079","document":"c91857_4x1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/310158/000120919109051079/c91857_4x1.xml","form_type":"4"}}],"next_cursor":"2009-11-04T23:01:08.000000Z,220179"}